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A primary objective in postmarketing drug safety surveillance is to ascertain the re-
lationship between time-varying drug exposures and adverse events (AEs) related to
health outcomes. Surveillance can be based on longitudinal observational databases
(LODs), which contain time-stamped patient-level medical information including pe-
riods of drug exposure and dates of diagnoses. Due to its desirable properties, we
focus on the self-controlled case series (SCCS) method for analysis in this context.
SCCS implicitly controls for fixed multiplicative baseline covariates since each indi-
vidual acts as their own control. In addition, only exposed cases are required for the
analysis, which is computationally advantageous. In the first part of this work we
present how the simple SCCS model can be applied to the surveillance problem, and
compare the results of simple SCCS to those of existing methods.
Many current surveillance methods are based on marginal associations between
drug exposures and AEs. Such analyses ignore confounding drugs and interactions
and have the potential to give misleading results. In order to avoid these difficulties,
it is desirable for an analysis strategy to incorporate large numbers of time-varying
potential confounders such as other drugs. In the second part of this work we propose
the Bayesian multiple SCCS approach, which deals with high dimensionality and can
provide a sparse solution via a Laplacian prior. We present details of the model and
optimization procedure, as well as results of empirical investigations.
SCCS is based on a conditional Poisson regression model, which assumes that
events at different time points are conditionally independent given the covariate pro-
cess. This requirement is problematic when the occurrence of an event can alter the
future event risk. In a clinical setting, for example, patients who have a first myocar-
dial infarction (MI) may be at higher subsequent risk for a second. In the third part
of this work we propose the positive dependence self-controlled case series (PD-SCCS)
method: a generalization of SCCS that allows the occurrence of an event to increase
the future event risk, yet maintains the advantages of the original by controlling for
fixed baseline covariates and relying solely on data from cases. We develop the model
and compare the results of PD-SCCS and SCCS on example drug-AE pairs.
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Chapter 1
Introduction
Increasing scientific, regulatory, and public scrutiny focuses on the obligation of the
medical community, pharmaceutical industry, and health authorities to confirm that
marketed medical products and prescription drugs have acceptable benefit-risk pro-
files. Ensuring drug safety is an intricate and ongoing process that begins with
carefully designed randomized clinical trials prior to approval, and continues after
regulatory market authorization when drugs are in widespread clinical use. This is
the setting of postmarketing surveillance, which refers to the process of monitoring
the safety of prescription drugs that have already been approved for the marketplace.
Once drugs are out on the market they are taken by many more individuals and for
longer periods of time than they were during pre-approval trials. Due to the large
amount of data that is available, in postmarket analyses it may be possible to identify
adverse events (AEs) related to drug exposure that had not been previously detected.
Both the complexity and scale of the problem of postmarketing surveillance present
major challenges for statistical analysis and computation. Patients often take mul-
tiple drugs concurrently, or may take drugs in ways that differ from how they were
prescribed. It is also difficult to determine patients’ overall health status and whether
or not they may be taking other actions that influence the frequency and/or timing of
AEs. In addition to these challenges, data sources used for surveillance often contain
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tens of millions of individuals who are observed over the course of several years. These
individuals may experience tens of thousands of possible AEs. Furthermore, there are
tens of thousands of possible drugs that patients can be exposed to, which results in
millions of potential drug interactions. We are thus dealing with a large-scale problem
that is also subject to the complications of high-dimensionality.
The current surveillance approach of the U.S. Food and Drug Administration
(FDA) relies on its Adverse Event Reporting System (AERS), which is one of the
several spontaneous reporting systems (SRSs) that are in use for surveillance. SRSs
are based on data collected from spontaneous reports, which are voluntarily submit-
ted by consumers and healthcare professionals. These reports contain self-reported
information on suspected links between drug exposures and AE occurrences. Other
prominent examples of SRSs include the Yellow Card Scheme of the Medicines and
Healthcare Products Regulatory Agency (MHRA), and the international pharma-
covigilance program of the World Health Organization (the WHO Uppsala Monitor-
ing Center). In the post-approval environment, surveillance schemes based on SRSs
represent a cornerstone for the early detection of hazards related to drug exposure.
Some of the limitations of SRSs such as AERS are that the temporal informa-
tion may be unreliable, there may be bias due to under-reporting, over-reporting,
or duplicate reports, and no denominator or control group is available to provide a
comparison. The FDA relies primarily on adjusted 2×2 table summaries from these
reports in order to deduce the relationship between drugs and AEs. Such analyses may
give misleading results since they focus on marginal associations and do not adjust
for the presence of confounding drug exposures. In addition, methods based on 2×2
summaries ignore potential drug interactions and do not incorporate information on
the timing of AEs relative to exposures. Despite these limitations, analytic methods
for spontaneous reports have attracted considerable attention in the last decade, and
several different methods have become well established both in commercial software
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products and in the medical literature.
In recent years, several high-profile drug safety cases have raised concerns about
the strategies that are currently in use for postmarketing surveillance. One of the most
prominent cases was that of Vioxx (rofecoxib), which was an anti-inflammatory drug
manufactured by Merck & Co, Inc. Merck made a voluntary worldwide withdrawal of
Vioxx in September 2004 due to evidence of an increased risk of cardiovascular events.
At a U.S. Senate Finance Committee hearing on Vioxx in November 2004, an officer
from the FDA estimated that “nearly 28,000 excess cases of heart attack or sudden
cardiac death were caused by Vioxx” (Graham, 2004). As a response to the revelations
from the Vioxx case and other drug safety concerns, U.S. Congress mandated that
the FDA establish an active surveillance system to prospectively monitor the safety
of marketed medical products, including marketed prescription drugs, as part of the
2007 FDA Amendments Act (FDAAA) (FDA, 2007c). The FDA responded to the
passage of the FDAAA by launching the Sentinel Initiative, a long-term program
whose goal is to implement a nation-wide active surveillance system. The FDAAA
intends for healthcare information on at least 100 million people to be accessible by
the year 2012 (Platt et al., 2009).
The AERS of the FDA is a passive surveillance system in which safety information
is obtained only once reports are voluntarily submitted. In contrast, under an active
surveillance system regulators can initiate their own safety investigations in existing
data sources held by hospitals, insurance companies, and other healthcare information
providers. In active surveillance, a key difference is that information in data sources
is recorded automatically rather than submitted voluntarily. Data sources include
medical insurance claims databases and electronic health records (EHRs), which are
examples of longitudinal observational databases (LODs). These LODs contain time-
stamped patient-level medical information, including periods of drug exposure and
dates of diagnoses that can be used to examine safety risks.
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In analyses for postmarketing surveillance in LODs, the observed outcomes are
AEs related to diagnosed health conditions, e.g. myocardial infarction (MI), stroke,
asthma attack, etc. Our objective in the surveillance problem is to ascertain drug
safety by estimating the strength of the association between AEs and drug exposures
that vary over time. We would like our analysis approach to make use of information
on the frequency and timing of events, as well as control for potentially confounding
drugs. In our work we focus on the self-controlled case series (SCCS) method, which
is a model for the analysis of recurrent events whose features are well-suited for the
surveillance context.
The self-controlled case series method was proposed by Farrington (1995) in or-
der to estimate the relative incidence of AEs for assessing vaccine safety. SCCS is
used to analyze recurrent events and determine their association with time-varying
covariates. This method is based on a conditional Poisson regression in which the
conditioning step produces two beneficial properties. First, it automatically controls
for all multiplicative fixed baseline covariates without having to explicitly include
them in the model. This feature is particularly appealing in situations where data
provide too few baseline covariates to effectively adjust for confounding. Second,
only exposed cases (individuals who were both exposed to the drug and had at least
one event) need to be included in the analysis, which reduces the amount of data
required and is computationally advantageous. With SCCS, each individual serves as
their own control. In other words, SCCS compares outcome event rates during times
when a person is exposed to outcome event rates during times when the same person
is unexposed. In effect, the cases’ unexposed time lets us infer expectations about
what would have occurred during their exposed time had they not been exposed.
Whitaker et al. (2005) provides a tutorial of SCCS and Farrington and Whitaker
(2006) introduce a semi-parametric approach to the model.
Other related case-based methods have been developed within the epidemiological
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literature (e.g. Navidi, 1998; Suissa, 1995), many of which are variants of the case-
crossover design (Maclure, 1991). Case-crossover requires the choice of a comparator
time period to serve as a control for each individual, and models exposures in case
and control time intervals via conditional logistic regression. In case-crossover the
exposures are outcomes and analysis is conditional on events, whereas in SCCS the
events are modeled as random and exposures are conditioned upon. SCCS also dif-
fers from case-crossover in that it makes use of information available over the entire
observation interval for each individual without the need to select a control period.
The problem of postmarketing surveillance in LODs must contend with millions
of individuals and millions of potential drug exposure variables. In contrast, the
epidemiological applications of SCCS have exclusively focused on situations with rel-
atively small sample sizes and a manageable number of exposure variables of interest.
The size of the surveillance problem presents a major computational challenge, and
ensuring the availability of an efficient optimization procedure is essential for a feasible
implementation.
The construction and development of the SCCS model that we present throughout
this work differs from that in the work done by Farrington (e.g. Farrington, 1995;
Farrington and Whitaker, 2006). In Farrington’s framework, one would begin with
data that is limited to case-series and, as a result, analysis proceeds conditional on the
fact that only cases are being used. In our approach we argue that individual baseline
rates are nuisance parameters, which can be eliminated by conditioning on their
sufficient statistics. The fact that only case-series data are needed for the analysis
comes through as a by-product of conditioning.
Due to this difference in development, we uncovered a connection between the
SCCS method and the fixed effects Poisson (FEP) model for panel (longitudinal)
data, which is well-established in econometrics literature (e.g. Hausman et al., 1984;
Cameron and Trivedi, 1998; Winkelmann, 2000; Wooldridge, 2002). Many economet-
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ric applications of the FEP model have been to panel data on patents; for example,
Hausman et al. (1984) examined the relationship between time-varying R&D expen-
ditures and firm-level patent applications over time. The FEP model differs from
SCCS only in that all individuals have a common observation period length under
FEP, whereas in SCCS observation length may vary by individual. Establishing this
link between FEP and SCCS may help provide insight into properties of the SCCS
model; for example Wooldridge (1999) gives results for consistency of the FEP esti-
mator that hold as long as the conditional mean is correctly specified, and Hausman
et al. (1984) presents a variant based on the negative binomial distribution.
The remainder of this work is organized as follows. In Chapter 2 we introduce
the simple self-controlled case series model for surveillance and present analysis re-
sults based on data from LODs. In Chapter 3 we extend the SCCS model to include
multiple drug exposures. We propose a regularization approach and an efficient op-
timization procedure that enable analysis for surveillance in the presence of very
large numbers of drug exposure predictors. In Chapter 4 we propose a positive event
dependence model, which avoids a restrictive conditional independence assumption
that is required by the original SCCS model. Chapter 5 we provide a discussion and
concluding remarks.
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Chapter 2
Self-controlled case series for
postmarketing surveillance
2.1 Introduction
The objective in postmarketing surveillance is to estimate the strength of the asso-
ciation between adverse events (AEs) and drug exposures that vary over time. The
longitudinal observational databases (LODs) used in an active surveillance system
contain individual-level data on both the timing and frequency of AE occurrences,
and we would like to incorporate this information into our analysis approach. We fo-
cus on the use of the self-controlled case series (SCCS) model for this purpose. SCCS
is based on a conditional Poisson model for recurrent events, where the conditioning
step yields two main benefits. First, the model automatically controls for all mul-
tiplicative individual-level confounders that are fixed in time. Second, inference in
SCCS depends only on exposed cases (individuals who are both exposed to the rele-
vant drug and have at least one occurrence of the AE of interest), which substantially
reduces the amount of data required in the analysis.
SCCS has been used primarily in the context of vaccine safety studies and epi-
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demiological applications to provide further assessment of previously established as-
sociations. In contrast, postmarketing surveillance centers around risk identification,
which refers to the identification of new drug-AE associations. Risk identification
presents a novel area of application for the SCCS model. Furthermore, an active
surveillance system examines the strength of the potential relationship between all
possible pairs of drug exposures and AEs, rather than for a specific few. The SCCS
model has never been applied within this framework of large-scale surveillance, nor
has its use for this purpose been empirically evaluated. In this Chapter we endeavor
to take on both of these objectives. We present how SCCS can be applied to the
problem of active surveillance in LODs, where the goal is to identify new assocations
on a large scale. We compare the results of applying the simple SCCS model on a
claims database to those of disproportionality analysis (DP) applied to AERS data.
DP encompasses the primary class of analytic methods that are currently used for
surveillance in spontaneous reporting systems (SRSs) such as AERS. We examine
five example drug-AE pairs, and investigate whether using SCCS to analyze claims
data would have led to earlier detection of drug-AE associations than implementing
a DP analysis on SRS data. We also give results of using SCCS to discriminate
between drug-AE pairs with and without associations based on data from several
LODs. We compare these SCCS pair classification results to those obtained from
other surveillance methods.
2.2 Notation and model framework
We will focus here on the simple SCCS model in which there is one drug exposure and
one outcome AE of interest; this is analogous to the case of a simple linear regression
with one predictor and one response variable. To set up notation, let i = 1, . . . , N
index individuals. Events and exposures in LODs are recorded by date, so temporal
information is available down to the level of days. Days are indexed by d = 1, . . . , τi,
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where τi is the total number of days that person i is observed and (i, d) is their dth
day of observation. The number of events on day (i, d) is denoted by yid, and the
drug exposure status on that day is indicated by xid, where xid = 1 if i is exposed
to the drug on day d, and 0 otherwise. The observed sequence of exposures for i
is given by the vector xi = (xi1, . . . , xiτi)
T, and observed event counts on each day
are represented by yi = (yi1, . . . , yiτi)
T. Figure 2.1 below shows example longitudinal
data for two individuals where Vioxx is the relevant drug exposure and myocardial
infarction (MI) is the AE of interest.
Figure 2.1: Longitudinal traces for a 44 year-old male and a 78 year-old male who both
experienced MI and were exposed to Vioxx during the course of their observation.
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SCCS assumes that AEs arise according to a non-homogeneous Poisson process,
where the time-varying event rate is modulated based on drug exposure status. The
model presumes that person i has an individual baseline event rate of eφi , which is
constant over time, and that periods of drug exposure result in a multiplicative effect
of eβ on the individual baseline rate. In other words, the Poisson event rate for person
i on day d can be written as
λid = e
φi+βxid ,
and eβ gives the relative risk of an AE during exposure. The number of events
yid conditional on the current exposure status xid is distributed as a Poisson random
variable with density




The Poisson likelihood for person i over their entire observation period is the joint
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density of their observed events, given observed exposures. This can be written as
Li = p(yi | xi) =
τi∏
d=1











There are two assumptions implicit in the Poisson model that allow us to write
the likelihood expression in the factorized form in (2.1), namely:
(i) Events are conditionally independent given exposures
yid ⊥ yid′ | xi for d 6= d′
(ii) Past events are conditionally independent of future exposures given the current
exposure status
yid ⊥ xid′ | xid for d 6= d′
These assumptions are likely to be violated in practice, e.g. one might expect
that having an MI may increase the future risk of an MI, which would violate (i), or
impact future drug usage, which would violate (ii). In Chapter 4 we propose a model
that circumvents assumption (i) by allowing for a positive dependence parameter to
be added to the baseline event rate each time that an AE occurs. In the discussion
in Chapter 5 we will consider other methods and future directions of work that deal
with these assumptions and other modeling difficulties.
If individuals are independent, the full likelihood is the product of the individual
Li likelihood contributions. One could then maximize the full log-likelihood over all
individuals in order to estimate the parameters. However since our main objective is
to assess drug safety, the drug effect β is of primary interest and the person-specific
φi effects can be treated as nuisance parameters. A further complication is that the
LODs used for postmarketing surveillance can contain well over 10 million patients.
Since the dimension of the vector of person-specific parameters φ = (φ1, . . . , φN)
T is
equal to the number of individuals N , estimation of φ would call for optimization in an
ultra high-dimensional space and presumably would be computationally prohibitive.
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In order to avoid estimating these individual nuisance parameters, we can con-
dition on their sufficient statistics. This will remove the dependence on φi from the
likelihood expression. Under the Poisson model likelihood given in (2.1), the total
number of events observed for person i, denoted by ni =
∑
d yid, is a sufficient statis-
tic for the φi parameter. Since events follow a non-homogeneous Poisson process, the
number of events ni is also distributed as Poisson with mean equal to the cumulative
event rate over the entire observation period, i.e.




In our case the cumulative intensity is a sum (rather than an integral) because we
assume a constant event rate within each day. Conditioning on ni yields the SCCS
likelihood contribution for i, which is
Lci = P ( yi | xi, ni ) =
P ( yi | xi )









Notice that because ni is sufficient, the individual likelihood in the above expres-
sion no longer contains φi. This conditional likelihood takes the form of a multinomial,
but it differs from a typical multinomial regression (e.g. see Agresti, 2002) in that
the number of “bins” (observed days τi) varies by person, the β parameter is constant
across days, and the covariates xid vary by day.












In the SCCS model the drug effect parameter is estimated by maximizing the
conditional log-likelihood corresponding to (2.3) to obtain βˆ. It is clear from the
expresson for the SCCS likelihood in (2.3) that if person i has no observed events
(yi = 0), they will have a likelihood contribution of L
c
i = 1. Such a person would
have no effect on the estimation, and as a consequence only cases (ni ≥ 1) need
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to be included in the analysis. SCCS does a within-person comparison of the event
rate during exposure to the event rate while unexposed, and thus the method is
“self-controlled”. Intuitively it follows that if i has no events they cannot provide
any information about the relative rate at which they have events. That the SCCS
analysis relies solely on cases is a substantial computational advantage: since the
incidence rate of most AEs is relatively low, typical SCCS analyses will utilize only
a modest fraction of the total number of individuals. In fact, even from the limited
pool of patients who had AEs, only those that experienced drug exposure during their
observation need to be included; this feature will be discussed in Section 3.2.2 of the
subsequent Chapter 3.
In the LODs used for surveillance, AEs are identified on the basis of diagnosis
codes associated with a particular date. This means that at most one AE can occur
on a given day, and so in reality yid = 0 or 1 for all days d. Since in practice yid is a
binary variable, one could apply a logistic (Bernoulli) model within each day rather
than a Poisson model and perform a conditional analysis in a similar manner. In
Appendix B we show that the SCCS model is equivalent to this conditional Bernoulli
within-day model, which is a result of days being treated as the smallest increment
of time in which an event can occur in the non-homogeneous Poisson process that
SCCS is based upon (Cook and Lawless, 2007).
2.3 Comparison with disproportionality analysis
2.3.1 Background on DP analysis
Current global postmarketing surveillance efforts rely predominantly on SRSs, includ-
ing the Adverse Event Reporting System (AERS) of the U.S. FDA. These systems
were designed in order to provide early warnings for safety problems that were not
detected during pre-approval clinical development (Hauben et al., 2005). A number
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of methods have been applied to the analysis of SRSs, e.g. Praus et al. (1993); van
Puijenbroek et al. (2000); Orre et al. (2005), however the most widely used methods
are examples of disproportionality analysis (DP) methods. These methods quantify
pairs of drug exposures and AEs based on the degree to which the drug-AE combi-
nation co-occurs “disproportionally” often compared to what would be expected if
there were no association (Bate and Evans, 2009).
Individual records in SRS databases typically include limited demographic infor-
mation (e.g. age and sex), date of report, one or more drugs and one or more AEs.
Well-known examples of DP methods include the multi-item gamma-Poisson shrinker
(MGPS) (DuMouchel, 1999), proportional reporting ratio (PRR) (Evans et al., 2001),
reporting odds ratio (ROR) (Rothman et al., 2004), and the Bayesian confidence prop-
agation neural network (BCPNN) (Bate et al., 1998). DP methods are based on 2×2
contingency tables for all possible pairs of drugs and AEs, where each table classfies
reports according to the presence of a given drug-AE combination. An example 2×2
table categorizing the number of reports with co-occurrences of drug x and AE y is
shown in Table 2.1.






In our data analysis we focus on one widely-used DP method, MGPS, to provide a
comparison for the simple SCCS surveillance approach. MGPS focuses on the report-
ing ratio (RR), which is the number of co-occurrences of the drug-AE combination
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(where both are present) divided by the expected number of occurrences if the drug
and AE were independent. In Table 2.1 the reporting ratio for drug x and AE y is
RR =
w00(w00 + w01 + w10 + w11)
(w00 + w01)(w10 + w11)
.
RR is a sensible measure of disproportionality since if a drug is more likely to
cause a particular AE than another drug, it will typically receive a higher score.
If a drug and AE are stochastically independent, the measure will return a value
of one. In the SRS context, however, the number of co-occurrences of a drug and
AE (i.e. the count w00 in Table 2.1) is often small due to low AE incidence rates.
This can lead to substantial variability in disproportionality measures even though
there are often large numbers of reports overall. MGPS adopts a Bayesian approach
in order to address the issue of variability. MGPS imposes a prior distribution on
RRs that shrinks estimates toward their average value, which is typically close to
one. As a result, strong evidence is required from the data in order to return an
MGPS estimate of RR that is substantially larger than one, thereby reducing the
chance that an association will be falsely identified due to high variability (Zorych
et al., 2011). The MGPS estimate of RR is the Empirical Bayesian Geometric Mean
(EBGM), which is the geometric mean of the posterior distribution of the true RR. It
is suggested in DuMouchel (1999) that the 5th percentile of the posterior distribution
(EB05) be used to provide a more conservative measure than EBGM, where an EB05
≥ 2 provides evidence of an association.
2.3.2 Results
We will focus on five drug-AE combinations in order to compare the use of DP and
SCCS for surveillance. To analyze these five combinations, we applied the simple
SCCS method on a large-scale claims database and the MGPS method on SRS data
from the AERS database. The drug-AE pairs that we examined were:
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1. rofecoxib (Vioxx) and myocardial infarction (MI)
2. exenatide and acute pancreatitis
3. lapatinib and hepatotoxicity
4. estrogen and MI
5. simvastatin and cataracts
Evidence of an assocation exists for the first four analysis pairs. Rofecoxib (Vioxx)
was withdrawn worldwide in 2004 due to an increased risk of cardiovascular events,
including MI (Bresalier et al., 2005). In October 2007 the exenatide label was altered
to include a warning for acute pancreatitis, and the FDA issued a corresponding
alert (FDA, 2007b). However several previous SRS-based DP analyses yielded false
negative findings for this pair (Hauben and Hochberg, 2008). Lapatinib recieved a
label warning for hepatotoxicity in July 2008, but has not yet been confirmed as a
signal of suspected causality (FDA, 2008). An association between estrogen and MI
has been identified in some clinical trials, e.g. Manson et al. (2003). We included the
last pair, simvastatin and cataracts, as a false positive that was previously identified
as an association but was later discounted (Hauben et al., 2006). We would like to
compare how SCCS and the MGPS DP method perform in the face of this challenge.
The data source for our SCCS analysis was the i3 InVision Data MartTM database,
which contains longitudinal claims records from the United HealthCare insurance
plans, including insurance eligibility, pharmacy claims, medical claims, inpatient and
outpatient services utilization, and procedures with the associated diagnoses and
costs. The enrollees of the United HealthCare plans have both medical and pre-
scription benefit coverage, and are primarily a population of employees and their
dependents. All data are de-identified to comply with the Health Insurance Porta-
bility and Accountability Act (HIPAA), a federal law that establishes standards for
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protecting the privacy and security of health information. The data covers over 36
million individuals in the United States between May 1, 2000 and December 31, 2008.
Further details are given in Madigan et al. (2011).
The plots in Figure 2.2–2.6 show relative risk estimates and confidence intervals
from both the SCCS and MGPS approaches for the 5 drug-AE pairs over time. The
values shown for MGPS are EBGM estimates of the RR based on AERS data, and
the SCCS values are relative risks (eβ) based on the i3 claims data. The SCCS
relative risk and the EBGM reporting ratio are on comparable scales (the RR acts
as a surrogate for relative risk). Each risk estimate in the plots was generated using
only the portion of the data that was available up to the specified time point, and
bars correspond to 95% confidence intervals. We compare the estimates from SCCS
and MGPS over time in order to determine if an SCCS analysis in claims data could
yield earlier detection of an association than a DP analysis in AERS data.




























































For the Vioxx-MI pair in Figure 2.2, we can see that SCCS estimates a relative
risk that is statistically significant (i.e. the 95% confidence interval exceeds one)
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starting at the beginning of 2001. Beyond 2005, the EBGM estimate rises sharply
and plateaus at RR ≈ 13 in 2007 and 2008 (not shown). This increase in signal in
AERS is likely due to the high-profile safety hearing on Vioxx in late 2004, which
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may have caused submission of a large number of associated reports to AERS. If we
use the criterion EB05 ≥ 2, the EBGM estimate is not significant until the start of
2004. These results suggest that applying the simple SCCS analysis to claims data
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may have lead to detection of the Vioxx-MI assocation 3 years prior to when the drug
was pulled off the market in 2004.
For the exenatide-pancreatitis pair in Figure 2.3, MGPS shows an association at
the beginning of 2008 and SCCS estimates a slightly elevated relative risk at the
beginning of 2009. The label warning for exenatide was altered to include acute
pancreatitis in 2007 (FDA, 2007b), so it is conceivable that public awareness led to
an increase in AERS reports submissions and a larger subsequent risk estimate for
MGPS.
The lapatinib-hepatotoxicity results are given in Figure 2.4. Although the point
estimates were somewhat elevated for SCCS, there are too few cases for this pair to
be able to determine significance. The MGPS estimate is in a similar range at the
beginning of 2009, but again significance cannot be determined likely due to the small
amount of data available for this pair.
In Figure 2.5 we can see that SCCS estimates a significant estrogen-MI association
starting at the beginning of 2003. The relative risk from DP is steadily increasing
over time, however by the end of 2008 it still shows a somewhat negative assocation.
Figure 2.6 shows results for the simvastatin-cataract pair, which was included as
a false positive assocation. EBGM estimates for MGPS demonstrate an elevated risk,
but the EB05 does not pass the significance threshold. SCCS relative risk estimates
start with a slightly negative association, but are very close to one across time.
The 2001 detection of the Vioxx-MI association exhibits the potential of the simple
SCCS-claims approach to provide substantially earlier risk identification than the
standard DP-AERs analysis. For the pairs of exenatide-pancreatitis, simvastatin-
cataract, and lapatinib-hepatotoxicity the simple SCCS-claims analysis and the DP-
AERS method yielded similar results. SCCS-claims identifies an estrogen-MI risk that
is suggested by literature (Manson et al., 2003), but is not found using the DP-AERS
method and has not fully been established. In addition, neither the SCCS-claims
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nor the DP-AERS analysis identified the false positive pair of simvastatin-cataract.
Overall these results suggest that SCCS-claims performs similarly to or at least as
well as DP-AERS, but the early detection of Vioxx-MI for SCCS-claims demonstrates
its potential.
2.4 OMOP classification for drug-AE pairs
2.4.1 OMOP Background
The simple SCCS model for surveillance that we have introduced is part of a larger
library of methods that are being systematically evaluated by the Observational Med-
ical Outcomes Partnership (OMOP) project. Our work forms part of the overall
OMOP effort to develop and test analytic methods for postmarketing surveillance
based on LODs. OMOP’s centralized network of large-scale LODs provides a rich
source of real-world data for testing surveillance approaches, and acts as a prototype
for the structure of an actual nation-wide active surveillance system that would be
based on multiple data sources.
The OMOP project is a multi-year initiative that was established in order to
evaluate and make recommendations regarding potential analysis methods for active
surveillance in LODs (Stang et al., 2010). OMOP is assessing these methods on the
basis of systematic empirical investigations. The project is a public-private partner-
ship between the pharmaceutical industry, the FDA, academic institutions, and data
source owners, and is administered by the Foundation for the National Institutes of
Health. The objectives for OMOP are to determine the structure that is necessary
for an active surveillance system and to develop and test methods that can effectively
ascertain the benefit-risk profiles of marketed prescription drugs.
OMOP has access to a network of 10 large-scale LODs that cover 130 million lives
in total. Data sources in this network include medical insurance claims databases,
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provided by SDI Health, Humana, and Thomson Reuters, and several EHRs sourced
by the Regenstrief Institute, Partners Healthcare System, GE Centricity, and VA
MedSAFE. Performing analyses in these disparate databases is complicated by the
fact that information is originally recorded using differing coding schemes. OMOP
has greatly facilitated analysis efforts by mapping data sources to a common data
model, where information on drug exposure and AE occurrence is represented in a
consistent fashion across databases (Stang et al., 2010).
We use four of the OMOP databases (CCAE, MDCD, MDCR, and MSLR, whose
descriptions are given in Table 2.2 below) to evaluate the performance of the simple
SCCS approach when compared against other surveillance methods. Together these
databases cover approximately 75 million individuals. We used these four data sources
because they had full results available at the time of analysis; results are currently
being generated for the remaining OMOP databases.
Table 2.2: OMOP collaborator databases for SCCS evaluation (Stang et al., 2010)
Database Collaborator Insurance type Individuals
(millions)





MDCD Thomson Multistate Medicaid Medicaid 11.1
MDCR Thomson Medicare Supplemental Medicare Supple-
ment
4.4
MSLR MarketScan Lab Results Multiple 1.5
We will compare the results of the SCCS method to those of two other approaches:
disproportionality analysis (DP), and observational screening (OS). These methods
are currently in use for surveillance in different capacities. DP is one of the most
widely-used approaches for surveillance in SRSs, as discussed in Section 2.3.1. It
can be adapted for surveillance in LODs such as the OMOP databases; details of
adapting DP for this context are given in Zorych et al. (2011). OS is available in
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commercial safety software marketed by the ProSanos Corporation, which is one of
the OMOP collaborators. OS is based on screening rates, which give the number of
AEs that occur during drug exposure divided by the cumulative time spent exposed
to the drug. The measure of association for OS is the screening rate ratio, which is
the ratio of the screening rate in a target group to the screening rate in a comparator
group.
2.4.2 Health outcomes and drug exposures of interest
OMOP has defined 10 health outcomes of interest (HOIs), corresponding to outcome
AEs, that can be used to evaluate method performance. These outcomes represent
a portion of the health conditions that are of significant concern due to their medi-
cal severity, past association with drug exposures, or impact on public health. The
selected HOIs are: angioedema, aplastic anemia, acute liver injury, bleeding, hospi-
talization due to gastrointestinal (GI) ulcer, hip fracture, hospitalization, acute MI,
mortality after MI, and acute renal failure. Definitions for these health outcomes
were created using a rigorous literature review process; based on the evidence tables
and the investigators experience, a series of definitions for each outcome were cre-
ated ranging from broad diagnosis code-based definitions to precise definitions based
on a combination of coded diagnoses, coded procedures, and clinical laboratory re-
sults (OMOP, 2011). In our analyses we used the broadest definition for each health
outcome based on diagnosis codes from previously published evaluation studies.
In conjunction with these HOIs, OMOP has identified 10 drug exposures of interest
(DOIs). A portion of these DOIs are associated with the 10 HOIs defined above.
The DOIs are: angiotensin converting enzyme (ACE) inhibitors, amphotericin B,
antibiotics, antiepileptics, benzodiazepines, beta blockers, bisphosphonates, tricyclic
antidepressants, typical antipsychotics, and warfarin.
Based on these HOIs and DOIs specified by OMOP, there are 10×10 possible
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pairs of drugs and AEs that can be used to evaluate method performance. Of the
possible drug-AE pairs, 9 have been classified as positive associations where there
is believed to be an elevated risk of the outcome AE due to drug exposure. There
are 44 remaining drug-AE pairs that serve as negative controls, where it has been
determined that there is no relationship between the drug and the outcome. These
53 pairs were classified by consensus of an expert panel, who made their judgements
on the basis of drug product labels, published literature, and previous observational
studies of association (Stang et al., 2010). Of the 100 possible drug-AE combinations,
the 47 remaining pairs were not classified due to mixed evidence of an association
from the literature and expert review. Surveillance methods are assessed according
to their ability to distinguish the 9 positive association pairs from the 44 that are
negative controls. Figure 2.7 shows the 10×10 matrix of chosen drug-AE pairs with
positive and negative pairs indicated.
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We can use these 53 pairs to gauge performance by treating this as a classfication
problem on drug-AE pairs. Each method results in a particular categorization for
each of the pairs as either a positive (+) association or negative (–) control. Table
2.3 shows the confusion matrix associated with the classification, which tabulates the
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number of pairs that are correctly (true positive, true negative) or incorrectly (false
positive, false negative) classified by a method. The performance metrics that we
will use to compare different methods are based on the categories in the confusion
matrix. A method’s true positive rate, or sensitivity, refers to the number of positive
associations that are correctly classified out of the total number of positives, i.e.
a/(a + c) in Table 2.3. The false positive rate, or 1–specificity, is the number of
negative controls that are incorrectly classified out of the total number of negatives,
i.e. b/(b+ d).













9 44 53 total
For the simple SCCS method and the other comparison approaches the level of
association for each drug-AE pair is determined by the value of a corresponding
point estimate. Pairs are classified as positive or negative based on whether or not
the point estimate for the pair surpasses a specific threshold. In the simple SCCS
model, for example, the relative risk estimates for each drug-AE pair can be ranked
as eβˆ(1) < · · · < eβˆ(M) with M being the total number of pairs. A threshold level c is
set such that any pair with an estimate eβˆ(m) where m > c is classified as positive,
and pairs that have m ≤ c are negatives. For the M = 53 drug-AE pairs in question
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there are M + 1 = 54 possible choices for the threshold c, each choice of which results
in a different classification outcome.
A portion of our performance metrics are based on the reciever operating char-
acteristic (ROC) curve, which plots sensitivity versus 1–specificity for a particular
method. In our classification problem each point on the plot corresponds to a
unique choice for the threshold c, and these M + 1 points determine the shape of
the ROC curve. A good classifier should maximize the sensitivity while minimizing
1–specificity, so an ideal ROC curve would have a sharp corner close to the upper
left-hand corner of the plot. A ROC curve of this type would also have a large
corresponding area under curve (AUC), which is the first metric we will use in our
assessment. AUC gives the probability that the method will rank a randomly chosen
positive association higher than a randomly chosen negative control, so a value of
AUC = 1 coincides with a perfect classification model and AUC = 0.5 is equivalent
to random guessing. Methods that are better at classifying drug-AE pairs will have
higher values of AUC, and it has been suggested that AUC is a better summary
measure of classification performance than overall accuracy (Bradley, 1997).
Large values of 1–specificity are undesirable because they correspond to a high
proportion of false positives, and it is unlikely that in practice we would choose a
threshold c that yields such values. Desirable thresholds result in a low proportion
of false positives, so it is really the left-hand portion of the ROC curve that reflects
method performance for a realistic range of thresholds. In order to assess methods
based on workable thresholds, we measure the partial area under curve (PAUC). This
gives the area under the ROC curve up to a cut-off at a certain level of 1–specificity;
in our case we chose a cut-off of 30%, so the maximum possible PAUC would be 0.3.
For the 30% cut-off, random prediction corresponds to PAUC = 0.045.
Our next metric is the mean average precision (MAP) score. MAP is based on
rank ordering the estimates for all pairs, placing cut-off points at the locations of
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each of the positive associations, and averaging over the precision achieved at each of
these cut-offs. For example, for the ordered estimates eβˆ(1) < · · · < eβˆ(M) in the simple
SCCS model, cut-offs c1, . . . , c9 are set to match the indices of the nine drug-AE pairs
with positive associations. The precision at cut-off c is calculated as the proportion
of true positives out of the total number of pairs classified as positive, i.e. a/(a + b)
in Table 2.3. The MAP score is then simply the average of the precision values at
the thresholds c1, . . . , c9.
There are two final performance metrics. The sensitivity at a 5% false positive
rate (Sensitivity at 5%) is the sensitivity level when c is set to achieve a 5% false
positive rate, i.e. it gives the height of the ROC curve at 5% 1–specificity. The
average false positive rate (Average FPR) is the simple average of the false positive
rates that are obtained by setting the thresholds c1, . . . , c9 to match the indices of the
positive association pairs. Unlike our other metrics, smaller values of Average FPR
correspond to a lower proportion of false positives and better method performance.
2.4.3 Results
The plots in Figure 2.8 show classification results for the 53 chosen drug-AE pairs
for the three comparison methods over all four OMOP databases. The numerical
values used to generate Figure 2.8 are given in Table 3.1 in the subsequent Chapter
3. Each method has multiple parameter settings that correspond to various design
decisions, including definition of time-at-risk, identification of AEs based on first
occurrence or all occurrences of diagnosis codes, and choice of comparator group
(Ryan et al., 2011). In our analyses we used the parameter settings for each method
that were source optimal based on AUC, i.e. that yielded the highest AUC for the
particular data source under investigation. Since the parameter settings were chosen
to maximize AUC, the performance metrics in our investigation are optimistically
biased. For a more accurate performance assessment one would need a larger number
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of drug-AE pairs, and parameter settings would be chosen based on hold-out data or
cross-validation. These directions are discussed in Chapter 5.
For four of the performance metrics (AUC, PAUC at 30%, Sensitivity at 5%
and Average FPR), the simple SCCS model was the highest performing method
for three out of the four databases. For the remaining metric, MAP score, SCCS
outperforms the other methods on all four of the databases. In addition, simple
SCCS is consistently best across all five metrics for both the CCAE and MDCD
databases, which are the two largest LODs in our study in terms of number of lives
covered. This suggests that SCCS is doing well on the pair classification problem
compared with the other methods in our investigation.
AUC values for the simple SCCS model ranged from 0.7 to 0.74 on CCAE, MDCD,
and MDCR, which suggests reasonable ability to discriminate between positive and
negative pairs in these databases. For MSLR the AUC for SCCS was 0.68. In general
SCCS had lower performance for the smaller databases (MDCR and MSLR), which
are subject to a higher degree of variability. This effect may be mitigated by meta-
analyses or combining information across databases (e.g. see Ryan et al., 2011),
which is an avenue for future investigation. When using PAUC in place of AUC,
SCCS does better on MSLR than the other methods (PAUC = 0.098), and maintains
the highest scores for CCAE and MDCD (PAUC = 0.099 and 0.107, respectively).
DP outperforms SCCS on MDCR, where for DP the PAUC = 0.119 and for SCCS
the PAUC = 0.099. Simple SCCS is consistently highest in terms of MAP score, with
values ranging from 0.39 to 0.45 across all databases. SCCS was also consistently
highest for Sensitivity at 5%, however it is difficult to base an assessment on this
metric since the small number of positive pairs leads to there being only a few possible
values for sensitivity (true positive rate). For CCAE, MDCD, and MDCR, simple
SCCS had the lowest range for Average FPR between 0.27 and 0.3, and for other
methods values ranged from 0.3 to 0.35. On MSLR, DP was the best performer with
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Average FPR = 0.26, whereas for SCCS the Average FPR = 0.32
The results of the drug-AE pair classification problem provide a preliminary as-
sessment of the simple SCCS model for postmarketing surveillance. As would be the
case for any evaluation procedure, the pair classification problem has some limita-
tions that should be noted. First, evaluation results are contingent upon the correct
categorization of pairs into positive associations and negative controls. Positive pairs
were identified on the basis of product labels, previous observational studies, and ex-
pert consensus, however it is concievable that some of these assocations either do not
exist or are not identifiable within the LODs in our analysis. Furthermore, since the
drugs under investigation have been on the market for a significant amount of time, it
may be the case that clinical practice has adapted in order to mitigate the occurrence
of AEs known to be associated with these drugs. The precision of the performance
measures is also limited by the small number of 53 drug-AE pairs available for testing,
and a more accurate judgement of performance would require a larger number of test
cases. OMOP is currently working to expand the number of available drug-AE pairs
for testing, and assessing the simple SCCS model and other analysis approaches on
this expanded test set will be part of our future work.
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Figure 2.8: OMOP evaluation metrics for simple SCCS and comparison methods on
4 OMOP databases
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(d) Sensitivity at 5%
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Chapter 3
Bayesian multiple SCCS for
surveillance in large-scale LODs
3.1 Introduction
In the previous Chapter 2 we focused on the simple SCCS model in which there was
one AE and one drug of interest. In reality, however, patients in LODs typically
take multiple drugs throughout the course of their observation period. Simple SCCS
only examines marginal associations between drugs and AEs, which is analogous to
the perspective of DP methods that depend on 2×2 table summaries for each drug-
AE combination. Basing analysis on marginal associations is problematic because it
ignores the presense of other drug exposures that may be potential confounders.
For instance, one particular kind of confounding risk has come to be known as the
innocent bystander effect in the drug safety literature. As an example, consider two
drugs, A and B, where A causes nausea and B does not. Suppose that drug A can
also cause a rare infection, and that patients on drug A are often prescribed drug B
to treat these infections. Since the infection is rare, drug B is not often prescribed for
patients who are not on drug A. Marginally, it may appear that drug B is associated
CHAPTER 3. BAYESIAN MULTIPLE SCCS FOR SURVEILLANCE IN
LARGE-SCALE LODS 31
with nausea when in fact this is not the case; here drug B is the innocent bystander.
To avoid such spurious associations due to confounding, it is desirable for an analysis
strategy to be able to control for the presence of other drug exposures when estimating
the effect for a particular drug.
In addition, patients in LODs are often prescribed to multiple drugs concurrently,
so there is a potential for interaction effects during intervals of time where different
drug exposures overlap. In order to incorporate multiple drug exposures and interac-
tions, the Poisson event rate in the SCCS model can be extended in a natural way.
We refer to this extension as the multiple SCCS model to differentiate it from the
simple SCCS analysis that was introduced in Chapter 2.
The multiple regression version of SCCS is referred to in work done by Farrington
(e.g. see Farrington, 1995; Whitaker et al., 2005; Farrington and Whitaker, 2006)
in the context of epidemiological and vaccine safety studies. However the problem
of postmarketing surveillance presents a unique challenge due to the large number
of drug exposure predictors that are involved. In order to handle this challenge of
high-dimensionality, we take a Bayesian approach to regularize the regression and
avoid the difficulties of overfitting that can result from using standard maximum
likelihood estimation. In our approach inference is based on maximum a posteriori
(MAP) estimation, which requires maximizing the log posterior for the drug effect
parameter vector. We propose using the cyclic coordinate descent (CCD) algorithm
for optimization due to its simplicity and efficiency for large problems. We present
results of our Bayesian multiple SCCS analysis for the drug-AE pair classification
problem on five OMOP databases, and compare its performance with that of several
other existing analysis methods for surveillance.
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Figure 3.1: Longitudinal traces for a 78 year-old male and a 24 year-old female who
both experienced an MI and were exposed to multiple drugs (celecoxib, olanzapine,
quetiapine, and Vioxx) during observation. Periods where drug exposures overlap










































To set up notation for the multiple SCCS model, suppose that there are p different
drugs of interest indexed by j = 1, . . . , p. On day (i, d) drug j has a corresponding
exposure status indicator where xidj = 1 if i is exposed to j on day d, and 0 otherwise.
The vector of drug exposures for (i, d) can be written as xid = (xid1, . . . , xidp)
T, and
the vector of observed event counts over all days is yi = (yid, . . . , yiτi)
T as before. Let
eβj be the relative risk due to drug exposure j, which acts multiplicatively on the
baseline rate eφi during periods of time where i is exposed to j. Figure 3.1 shows
example data for two patients with multiple drug exposures and MI as the outcome
AE of interest.
The Poisson rate on day (i, d) takes the form
λid = e
φi+β
Txid = eφi + β1 xid1 + ··· + βp xidp ,
where β = (β1, . . . , βp)
T is the vector of drug effect parameters. The total num-
ber of events ni is again sufficient for φi under this multiplicative model, so the
person-specific nuisance parameters will once again drop out of the likelihood upon
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conditioning. One can derive the full conditional likelihood in a similar manner as
















To simplify the summation in the denominator, days with common drug exposures
can be grouped together within person. Each day (i, d) can be categorized into an
exposure group based on the combination of drugs that i is taking on that day.
Suppose that i experiences Gi distinct combinations of drug exposures, and that
these exposure groups are indexed by g = 1, . . . , Gi. We define Gi new exposure
vectors x∗ig corresponding to these groups, where day d falls in group g if xid = x
∗
ig.
To calculate the multiple SCCS likelihood we need to know the number of events i
has while in exposure group g, denoted by y∗ig =
∑
d∈g yid, along with the number of
days d in group g, denoted by lig. Information is required only at the level of the Gi
groups, rather than for each of the τi days, which allows for more efficient storage
and computation; patients tend to take drugs over extended periods of time, so Gi is
typically much smaller than τi. The multiple SCCS conditional likelihood for i based














We can also build drug interactions and other relevant time-varying covariates
(e.g. age groups, measures of health taken over time, etc.) into the multiple SCCS
model in addition to drug main effects. For instance, suppose that γrs is the two-
way interaction effect between drugs r and s, and that zid is a vector of additional
time-varying covariates for (i, d) that are believed to effect AE occurrence. Then the





r 6=s γrs xidr xids + α
Tzid . (3.3)
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The event rate in (3.3) can be inserted into the conditional likelihood in (3.1) in a
straightforward manner, and the individual φi parameters drop out of the expression
as before. Under this expanded model, the grouping of days would be based on unique
combinations of drug exposures, interactions, and values of the zid covariates, and the
likelihood can be written in a grouped form similar to (3.2).
3.2.2 Inference and maximum likelihood estimation
Inference in the multiple SCCS model can be based on maximum likelihood estima-
tion. The SCCS log-likelihood is concave (Appendix A) so optimization can be done
in a variety of ways, e.g. by taking a multidimensional Newton-Raphson approach.
Standard asymptotic theory for maximum likelihood is applicable for multiple SCCS,
where the estimate βˆ is asymptotically distributed as (βˆ−β) ∼ N(0, I−1(β)) and I(β)
is the information matrix given in (3.6). We can estimate the covariance matrix for
βˆ by taking ˆcov(βˆ) = I−1(βˆ). Asymptotic Normality allows us to calculate (1−α)%
confidence intervals for the jth drug effect parameter βj by using βˆj ± zα/2
√
vˆar(βˆj),
where zα/2 is the (1− α/2) quantile of the standard Normal distribution and vˆar(βˆj)
is taken to be the jth diagonal element of the inverse information matrix I−1(βˆ). We
can use the delta method to obtain confidence intervals for the corresponding relative
risk eβj due to exposure j, where the (1 − α)% confidence interval takes the form
eβˆj ± zα/2 × eβˆj
√
vˆar(βˆj).
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The expected information matrix, i.e. the expected value of the negative of the





























where x⊗2 = xxT denotes the outer product. In this case the observed and
expected information matrices are equal since the Hessian depends only on ni and
xid, which are fixed through conditioning, and is independent of the random yid
outcomes.
We noted in Section 2.2 that the analysis is dependent only on data from cases.
From the expressions for the score vector U(β) in (3.5) and information matrix I(β)
in (3.6), we can see that unexposed cases (i.e. individuals i where both ni ≥ 1 and
xid ≡ 0 for all d) will not contribute to the estimation of βˆ or vˆar(βˆ) since they add a
zero element to the summations in U(β) and I(β). Thus only exposed cases need to
be included in the analysis, which leads to a substantial reduction in the amount of
data required. Of the already modest number of cases, we are able to exclude those
who were not exposed to at least one of the drugs of interest during the course of
their observation.
3.3 Bayesian multiple SCCS approach
Inference and analysis results are typically based on maximum likelihood estimates of
the drug parameter vector β, as discussed in Section 3.2.2. However, in the setting of
postmarketing surveillance there are millions of potential exposure predictors made up
of tens of thousands of drug exposure main effects along with their interactions. We
are thus dealing with a high-dimensional regression problem, where the maximum
likelihood approach can result in overfitting, large estimated coefficient variances,
numerical instability, and spurious effect estimates.
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In order to avoid the difficulties related to high-dimensionality, we take a Bayesian
approach to regularization by imposing a prior distribution on the drug exposure
parameter β. Priors are specified such that β is most likely to be near zero and large
parameter values will be more heavily penalized, which has the effect of shrinking the
posterior distribution toward zero. We perform inference based on MAP estimates,
which are equivalent to constrained maximum likelihood estimates in the regularized
regression framework where a restriction is placed on the norm of the parameter
vector. Well-known examples of regularized regression are ridge regression (Hoerl
and Kennard, 1970) and the lasso (Tibshirani, 1996). Efficient algorithms to find
MAP estimates are available, which makes the optimization tractable even in the
high-dimensional setting. There are many possible choices for priors on β, however
we focus on the Normal and Laplacian priors for simplicity.
For the first approach to Bayesian multiple SCCS we place an independent univari-
ate Normal prior with mean zero, variance σ2β on each of the parameter components
βj, which has the effect of pulling the estimates toward zero. A smaller choice of σ
2
β
will lead to a higher degree of shrinkage. The prior is specified as
βj | σ2β ∼ N(0, σ2β) for j = 1, . . . , p.
This choice of prior is equivalent to placing a ridge regression penalty on the likelihood,
which constrains the L2-norm of the parameter vector β. From the expression for
the corresponding posterior distribution in (3.7), we can see that for this prior MAP




As a second approach, we use an independent univariate Laplace distribution with
mean zero, variance 2/λ2 as the prior on each of the βj parameter components. This
Laplacian prior has the added advantage of inducing sparsity in the model: a portion
of the components of the MAP estimate of β will shrink all the way to zero and, as a
consequence, the drug exposure predictors associated with those components will not
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enter into the model. Larger values of λ lead to a greater degree of shrinkage and a
higher number of variables being selected out of the model. The prior is specified as
βj | λ ∼ Laplace(0, 2/λ2) for j = 1, . . . , p.
From the corresponding posterior distribution given in (3.8) we can see that MAP
estimates will be equivalent to maximum likelihood estimates with a lasso penalty.
Here the L1-norm of the parameter vector
∑p
j=1 |βj| is constrained in order to prevent
parameter estimates from getting too large.
Under the Normal and Laplace priors, respectively, expressions for the full log
posterior distributions for β in our Bayesian multiple SCCS model are









































Estimating β via MAP requires maximizing (3.7) or (3.8), depending on the prior
that is imposed. Our strategy for optimization is discussed in the subsequent Section
3.4. For a fully Bayesian analysis, ideally one would use Markov chain Monte Carlo
(MCMC) or other sampling techniques to obtain the full posterior distribution for
the β parameter. However, in our application the large number of drug exposure
predictors renders such approaches intractable. To estimate the variability and other
second order features of the posterior for β, it may be possible to make use of methods
that rely on approximations and are less computationally costly than MCMC. These
possibilities are discussed in the final Chapter 5 as a direction for future work.
CHAPTER 3. BAYESIAN MULTIPLE SCCS FOR SURVEILLANCE IN
LARGE-SCALE LODS 38
3.4 Optimization and implementation
Finding the MAP estimate for the β parameter depends on maximizing the SCCS log
posteriors given in (3.7) and (3.8). If we frame this optimization as a minimization
problem, the objective function for Bayesian multiple SCCS is the negative of the log
posterior. In Appendix A we show that the multiple SCCS likelihood is log concave
in β. Since the density functions for both the Normal and Laplacian priors on β are
also log concave, it follows that the negated log posterior is a convex function. The
objective function we are using for MAP estimation is thus amenable to algorithms
that are specialized for convex problems.
There are many possible strategies for convex optimization, however we choose to
use the method of cyclic coordinate descent (CCD). The advantages of CCD are that
it is straightforward to implement and it has been demonstrated to have high speed for
large problems (Wu and Lange, 2008). Convergence properties of CCD are discussed
in Tseng (2001) and Saha and Tewari (2010). The CCD algorithm is comparable
to approaches used in state-of-the-art software packages for regularized regression,
namely the open-source Bayesian binary regression (BBR) software of Genkin et al.
(2007) and the glmnet R package of Friedman et al. (2010). Our development follows
that of Genkin et al. (2007), which is based on the CLG algorithm of Zhang and Oles
(2001).
CCD works by cycling through each component of the parameter vector and doing
a one-dimensional minimization update for the chosen component while holding the
values of the other components constant. The process continues for each parame-
ter component in turn, and the algorithm makes multiple passes over the full vector
until a suitable convergence criterion is met. This procedure enjoys substantially re-
duced computation time when compared with the multidimensional Newton-Raphson
approach or similar methods; CCD relies on one-dimensional updates, which circum-
vents the need for processing and storage of a high-dimensional Hessian matrix.
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The details of the algorithm are as follows. Let k = 0, 1, . . . index the number of
times that CCD has cycled through all j = 1, . . . , p components of the drug parameter
vector β. First, the value β(0) is initialized. For the jth component, g(z) is the
negated log posterior function that varies only along the dimension of βj while the
values of the other parameter components are held constant. On the kth iteration
of the algorithm, we would like β
(k)
j to be updated such that the new value β
(k+1)
j
minimizes the objective function with respect to the jth component, i.e.
β
(k+1)
j = arg min
z
g(z).
This one-dimensional minimization is done via Newton’s method, which depends on
the updating equation β
(new)
j = βj − g
′(βj)
g′′(βj)
. Expressions for g′(βj) and g′′(βj), the
first and second derivatives of the objective function g(z) evaluated at βj, are given
in (3.9–3.12). As described in Genkin et al. (2007), it is sufficient to take a single
minimization update step for the current component on each cycle of the algorithm
rather than doing the full minimization. Component values are updated on each cycle
of CCD, so there is little benefit to spending time finding the exact minimizer for one
component on a single cycle.
CCD uses a trust region approach in which the allowable update step size for each
component is thresholded in order to improve convergence. This type of approach
constrains jump sizes so that parameter updates stay within the region where the
quadratic function used in the Newton-Raphson step is a reasonable approximation










j . The magnitude of ∆β
(k)
j is thresholded by ∆
(k)
j ,
which is the upper limit for the jump size for βj on the kth iteration. This limit is
itself updated so that ∆
(k+1)
j = max(2|∆β(k)j |,∆(k)j /2) for iteration k + 1.
Expressions for the first and second derivatives of the component-wise objective
function g(z) are given in (3.9–3.12). We let rid = β
Txid for person i on day d.
This inner product depends on the current value of the parameter vector and is thus
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constant with respect to z. The first and second derivatives of the negative of the log



































































































for βj 6= 0, (3.12)
where sgn(x) = +1 if x > 0, and −1 if x < 0.
When β
(k)
j is updated on the kth iteration, the inner products rid are updated






j − β(k)j ). In postmarketing surveillance the
exposure vectors xid are sparse in that xidj = 0 for the majority of vector components
j. This sparsity is a result of individuals typically being exposed only to a small
subset of all possible drugs, and for that subset the exposures may not occur on the
majority of observation days. For efficient computation, the CCD implementation
keeps a current version of the inner product rid stored. This saves processing time
and takes advantage of the sparsity in the exposure vectors since if xidj = 0 then rid
does not need to be updated.
Under the Laplace prior, the values of g′(βj) and g′′(βj) are not defined at βj =
0 since the L1-norm constraint is not differentiable at that point. We follow the
approach of Genkin et al. (2007), which modifies the updates in the CCD algorithm to
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handle this special case. With this modification, β
(k+1)
j is set to zero on iteration k+1 if
the calculated jump ∆β
(k)
j would change the current sign of the parameter component,
i.e. if sgn(β
(k+1)
j ) 6= sgn(β(k)j ). In the case that the parameter component β(k)j = 0,
we attempt to update βj in both directions, sgn(βj) = +1 and sgn(βj) = −1, and
proceed with the update if the calculated ∆β
(k)
j would result in an update in the same
direction, i.e. ∆β
(k)
j > 0 for sgn(β
(k+1)
j ) = +1 and ∆β
(k)
j < 0 for sgn(β
(k+1)
j ) = −1.
The value is only updated if this criterion is passed; otherwise the component is kept
at zero. Since the objective g(z) is convex, either the −1 or the +1 direction will
result in a successful update, but not both. Parameters are selected out of the model
when components become locked to zero prior to the convergence of the algorithm.
3.5 OMOP data analysis
3.5.1 Background
In order to evaluate our Bayesian multiple SCCS approach, we would like our inves-
tigation to target two primary objectives: (1) determine whether Bayesian multiple
SCCS outperforms the simple SCCS analysis presented in Chapter 2, which only
considers marginal associations, and (2) compare the performance of the Bayesian
multiple and simple SCCS approaches to standard alternative surveillance methods.
We address these questions through empirical evaluation. Our empirical results are
based on the drug-AE pair classification problem described in Section 2.4.2 for the
health outcomes and drug exposure outcomes of interest defined by OMOP.
We will compare the results of applying Bayesian multiple SCCS for pair classifi-
cation to those of the simple SCCS method and three other approaches: dispropor-
tionality analysis (DP), observational screening (OS), and Bayesian logistic regression
(BLR). Open source software for these methods is available on the OMOP website,
http://omop.fnih.org. The DP and OS methods were referred to in Section 2.4.1.
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We chose to include BLR as an additional method in our comparison since it is a
regularized regression model that is similar in spirit to our Bayesian multiple SCCS
approach, and it is also well-suited to high-dimensional problems. BLR adjusts for
the presence of drug exposures and other potential confounders in a similar manner
as the multiple SCCS model. Multiple drug exposures can be included as predictors
in BLR, unlike in DP or simple SCCS where we are limited to marginal associations.
The BLR model is as follows. Let yi represent the presence or absence of the
AE of interest within the observation period for person i, i.e. yi = 1 if the outcome
AE occurs during observation and 0 otherwise. There are p drugs of interest, and
xi = (xi1, . . . , xip)
T is the corresponding vector of drug exposure indicators. For
inviduals with yi = 1, the exposure indicator is xij = 1 if i is exposed to drug j during
a window of time prior to the first occurrence of the condition, and 0 otherwise. The
length of this window of time is a parameter to be specified by the user. In our
BLR implementation for the HOI/DOI pair classification problem, the control group
(where yi = 0) is made up of a randomly chosen subset of individuals who did not
have the AE of interest, but did have an occurrence of at least one of the other HOIs.
For the group where yi = 0, one of the other HOI occurrences for i is randomly
selected. The drug exposure indicator is xij = 1 if i is exposed to drug j during a
window of time prior to the selected HOI occurrence, and is 0 otherwise. The values
of other pertinent fixed covariates such as age or sex could also be incorporated into




p(yi = 1 | β,xi)
p(yi = 0 | β,xi)
]
= β1xi1 + · · ·+ βpxip = βTxi, (3.13)
and β = (β1, . . . , βp)
T is the parameter vector of log odds ratios associated with
the p drug exposures. In BLR there is a prior imposed on the β drug effect parameter,
which can take the form of an independent univariate Normal or Laplace prior on each
of the βj parameter components. This shrinks MAP estimates and reduces overfitting
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in a similar manner as our Bayesian multiple SCCS approach, and helps mitigate the
number of false positive associations.
3.5.2 Evaluation results
In our evaluation we examine the same set of five performance metrics that we used
previously for the drug-AE pair classification problem: AUC, PAUC at 30%, MAP
score, sensitivity at 5%, and average FPR. We applied our comparison methods for
this problem to the four OMOP databases of CCAE, MCDC, MDCR, and MSLR. A
detailed description of the performance metrics and OMOP data sources is given in
Section 2.4.1.
Figure 3.2 shows results for the five analysis methods implemented on the four
OMOP databases. In the plot, SCCS refers to the simple SCCS method of Chapter 2
and BSCCS refers to the Bayesian multiple SCCS approach. For each analysis method
we chose parameter settings that were source optimal based on AUC, as described
in Section 2.4.3. Table 3.1 gives the full list of numerical values that were used to
generate Figure 3.2, with the best performers highlighted for each combination of
evaluation metric and database.
For both AUC and Average FPR, the BSCCS approach is consistently the best
performer out of the five methods across all four databases. The AUC values for
BSCCS range from 0.75 to 0.82, suggesting that the method does relatively well in
discriminating between a randomly chosen positive and negative pair. SCCS had
the second highest AUC values for CCAE and MDCR (0.74 for both), with BLR
being second highest for MDCD (AUC = 0.8) and DP being second for MSLR (AUC
= 0.74). For PAUC at 30%, BSCCS has the highest values on CCAE and MDCR
(PAUC = 0.12 for both), and BLR has the highest for MDCD and MSLR (PAUC =
0.17 and 0.12, respectively.
BSCCS had the best MAP score performance for the three largest databases
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(CCAE, MDCD, and MDCR). BLR had the highest MAP for MSLR, with BSCCS
being second. BLR has the highest Sensitivity at 5% values for CCAE and MSLR,
and BSCCS was highest for MDCD and MDCR. As noted in Section 2.4.3, this
metric is difficult to use for comparison here since there is a small number of positive
pairs. In general BSCCS outperformed SCCS across all metrics and data sources, the
only exceptions being PAUC at 5% and Specificity at 5% for MSLR. This suggests
that adjusting for multiple drug exposures and regularizing the regression leads to
improved performance in terms of drug-AE pair classification.
The ROC curves for the five methods across all four databases are shown in Figure
3.3. The larger points on the curves correspond to the locations of the 9 positive
associations. The sensitivity value rises at each of these locations since passing that
threshold increases the number of true positives detected by one. Based on the ROC
curves, we can see differences in method performance in more detail. For PAUC at
30%, for example, we can see that BLR is outperforming BSCCS on MDCD and
MSLR. The ROC curves demonstrate that BLR is able to detect a higher number
of true associations at lower levels of 1–specificity than BSCCS on these databases
(i.e. the ROC curves for BLR rise more steeply for values of 1–specificity near zero).
Despite this, BSCCS tends to place true positives at low levels of 1–specificity overall,
resulting in low Average FPR compared to other methods. We can also see that in
general OS has lower AUC values, since its ROC curves lie closer to the diagonal
(AUC = 0.5, which corresponds to random guessing) than the other methods.
Figure 3.4 shows BSCCS relative risk estimates for the 53 drug-AE pairs plotted
against those for simple SCCS on the four OMOP databases. The enlarged red
squares correspond to positive association pairs and the smaller black squares are
the negative control pairs. The dashed diagonal line is where BSCCS and SCCS
estimates are equal. We can see that estimates tend to lie below the diagonal, so the
shrinkage in BSCCS typically leads to relative risk estimates that are smaller than
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those from SCCS. For MDCR and MSLR, there is one positive assocation pair where
BSCCS estimates are higher than those from SCCS; this difference may be due to the
adjustment for confounding drug exposures in the BSCCS model. In CCAE, MDCD,
and MDCR a noticeable portion of the negative control pairs tend to get a higher
degree of shrinkage from BSCCS than the positive associations since they lie farther
below the diagonal line. For MSLR it appears that, with the single positive pair as
an exception, both negative and positive pairs lie close to the diagonal. The lack of
shrinkage for the negative pairs for BSCCS compared to SCCS on MSLR may be one
of the reasons that BSCCS generally does not do as well on this database as it does
for the other three.
These evaluation results are subject to the same limitations that were laid out
in Section 2.4.3, however they provide a means of preliminary assessment for our
BSCCS model. These results demonstrate that BSCCS often is the highest performer
compared to the other methods on our 4 OMOP databases. In particular, BSCCS
has better performance than the simple SCCS model across the majority of metrics
and databases, which suggests that adjusting for confounding drug exposures and
regularizing the regression leads to improved ability to discriminate between positive
and negative drug-AE pairs in our experiment. BSCCS also tends to score higher than
BLR, which indicates that having the recurrent nature of outcome AEs incorporated
into the model may also improve method performance.
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Figure 3.2: OMOP evaluation metrics for Bayesian multiple SCCS and comparison
methods on 4 OMOP databases













































(b) PAUC at 30%













































(d) Sensitivity at 5%
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Figure 3.3: ROC curves
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Figure 3.4: BSCCS vs. SCCS pair estimates for four OMOP databases
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Table 3.1: Results of method comparison on OMOP databases







DP 0.687 0.068 0.288 0.111 0.313
OS 0.679 0.089 0.298 0.111 0.321
BLR 0.727 0.121 0.469 0.333 0.273
SCCS 0.735 0.099 0.453 0.222 0.265
BSCCS 0.818 0.125 0.511 0.222 0.182
MDCD
DP 0.697 0.081 0.304 0.111 0.303
OS 0.679 0.086 0.287 0.111 0.321
BLR 0.798 0.168 0.547 0.333 0.202
SCCS 0.705 0.107 0.481 0.333 0.295
BSCCS 0.811 0.160 0.585 0.333 0.189
MDCR
DP 0.682 0.119 0.346 0.111 0.318
OS 0.654 0.058 0.254 0.000 0.346
BLR 0.682 0.106 0.330 0.111 0.318
SCCS 0.735 0.099 0.389 0.111 0.265
BSCCS 0.763 0.122 0.435 0.111 0.237
MSLR
DP 0.740 0.074 0.373 0.111 0.260
OS 0.672 0.091 0.304 0.111 0.328
BLR 0.715 0.124 0.462 0.333 0.285
SCCS 0.684 0.098 0.386 0.222 0.316
BSCCS 0.753 0.097 0.394 0.111 0.247
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Chapter 4
A positive event dependence model
4.1 Introduction
Events in the SCCS model arise from a non-homogeneous Poisson process, which re-
lies on implicit assumptions regarding conditional independence. The model assumes
that, within individuals, event occurrences are conditionally independent given expo-
sures. This is conditional independence assumption (i) discussed in Section 2.2. This
requirement is clearly violated when the occurrence of an event can alter the risk of
future events. In a clinical setting, for example, once a patient has a first MI they
may be at higher subsequent risk for a second MI. In the application of postmarketing
surveillance many AEs exhibit this type of behavior, so we would like be able to an-
alyze the association between drug exposures and AEs without requiring conditional
independence.
General intensity-based models for recurrent events can incorporate functions of
the event history, such as cumulative event count or time elapsed since the most recent
event, into the process intensity in order to represent dependencies between event
occurrences (Cook and Lawless, 2007). Although these models allow for dependence,
they lack the desirable properties that result from conditioning in SCCS. There have
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been recent efforts to model and investigate event dependence within the framework
of the SCCS model. Hocine et al. (2005) developed a method to test for independence
between different types of events in a bivariate setting, and Farrington and Hocine
(2010) present a method that extends SCCS by imposing a dependence function in
the intensity of a multidimensional Poisson model.
In this Chapter we propose a model that does not require the assumption of
conditional independence between event occurrences. We refer to our generalization
as the positive dependence self-controlled case series (PD-SCCS) method in order to
emphasize that dependence is due to a positive term added to the baseline event
risk. PD-SCCS lets individual risks increase additively through the inclusion of a
birth process component and, as such, models a type of dependence that cannot
be incorporated in Poisson process-based methods. At the same time our model
preserves the key advantages of the original SCCS model: it automatically adjusts
for multiplicative fixed baseline covariates without explicitly including them in the
model, and data requirements are reduced since the analysis depends only on cases.
Fixed individual-level baseline parameters drop out of the likelihood, as they do in the
SCCS model. Data sources used for postmarketing surveillance can contain upwards
of tens of millions of people, so in this context it is particularly advantageous that
PD-SCCS avoids doing a costly estimation of these individual parameters. We will
develop expressions for large sample inference and optimization based on the PD-
SCCS conditional likelihood and compare the results of our generalized model with
the more restrictive SCCS approach. The PD-SCCS model is developed and given a
detailed treatment in Simpson (2011).
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4.2 Model specification
4.2.1 Notation and framework
Suppose that there are N individuals in the data, indexed by i = 1, . . . , N . Person i
is observed over an interval of time (ai, bi] of length τi = bi − ai, where the unit of
duration may be taken to be calendar time, age, or another appropriate measure. Let
Ni(ai, t) represent the number of events that i experiences during the time interval
(ai, t]. For ease of notation we will write Ni(t) = Ni(ai, t) where the time interval
is understood to begin at ai and {Ni(t), ai ≤ t} is the counting process for events
experienced by i. Assume that ni is the total number of events observed for i, i.e.
Ni(bi) = ni. These events occur at times ti1 < · · · < tini , where tij corresponds to the
time of the jth event for i. We assume that time is continuous and that there are no
ties between event times.
Our objective is to determine the association between the event process and a
set of relevant time-varying covariates. Suppose that there are p such covariates,
indexed by k = 1, . . . , p, whose values for person i at time t are represented by the
vector xi(t) = (xi1(t), . . . , xip(t))
T. We focus on the case where covariates represent
exposure indicators, so that the kth element of the vector may be written as xik(t)
= 1 if i experiences exposure k at time t and xik(t) = 0 otherwise. This leads
to simplifications in storage and computation, and is the form we will use in our
examples. It is also valid, however, for the covariate vector xi(t) to be made up of
general (non-indicator) functions of time.
The process history at time t is denoted by Hi(t) = {Ni(s) : ai ≤ s < t}, which
comprises all past values of the counting process for i until time t−. An event process
such as Ni(t) can be defined in terms of its intensity function λi(t | Hi(t)), which
gives the instantaneous probability that an event occurs at time t given the process
history (Cook and Lawless, 2007). In our development the intensity function at t is
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also conditional on the current covariate history {xi(s) : ai ≤ s ≤ t}, but in order
to simplify notation this will not be explicitly stated. In addition, all likelihoods and
probability statements should be assumed to be conditional on covariate history.
4.2.2 Poisson-based continuous time SCCS model
To allow for person-level heterogeneity, each person i is assumed to have an individual
baseline intensity of eφi . During any intervals of time where i is exposed to variable
k, there is a multiplicative effect of eβk on the baseline intensity, i.e. eβk gives the
relative risk of an event due to exposure k. Letting β = (β1, . . . , βp)
T denote the
vector of effects for the p exposures, the SCCS intensity for i at time t can be written
as
λi(t | Hi(t)) = eφi+xi(t)Tβ. (4.1)
The intensity function in (4.1) is that of a Poisson process because at any time
point t it is independent of the current process history Hi(t). The likelihood con-
tribution of i follows from the probability density of observing ni events at times















In many applications, β is the parameter of interest because it determines the
relationship between events and exposures. On the other hand the individual pa-
rameter φi provides no information about this relationship and can be treated as a
nuisance parameter. The factorization theorem implies that the observed number of
events ni is a sufficient statistic for φi. As a consequence, conditioning on ni will
remove φi from the likelihood expression for i.
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Since Ni(t) follows a non-homogeneous Poisson process, the total count Ni(bi) is
a Poisson random variable with mean
∫ bi
ai
λi(u | xi(u))du. The value of this Poisson
density for Ni(bi) at ni yields the term in the denominator.
4.2.3 Our proposed PD-SCCS model
The intensity function for our proposed PD-SCCS model for person i at time t takes
the form
λi(t | Hi(t)) = (eφi + δ Ni(t−)) exi(t)Tβ. (4.3)
The intensity in (4.3) varies according to the event count Ni(t
−) just prior to time
t, which is part of the process history Hi(t) that is conditioned upon. Due to this
dependence on Hi(t), events no longer follow a Poisson model, but instead arise from
a non-homogeneous pure birth process with immigration (Parzen, 1964). At time t an
event occurs either as an “immigrant” from a non-homogeneous Poisson process with
intensity eφi+xi(t)
Tβ or as a “birth” with intensity δNi(t
−)exi(t)
Tβ. Since a process
intensity must be non-negative, we restrict the space of the dependence parameter
to δ ≥ 0. When δ = 0 the PD-SCCS intensity model in (4.3) reduces to that of the
SCCS model in (4.1).
For a general intensity-based process, the likelihood contribution for individual i
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From this likelihood expression we can see that ni is sufficient for the person-
specific parameter φi. This is a result of Ni(t
−) having an additive effect on the
baseline eφi ; if the event count were included as a multiplicative effect sufficiency
would not hold. Conditioning on ni removes the nuisance parameter φi from the
likelihood, as it did in the SCCS model.
Determining the conditional likelihood requires an expression for the density of
the total event count ni, which is found by integrating LPD,i over all possible ways


















Tβdti1 · · · dtini . (4.5)
The integral inside the exponential term is a function of the ordered times ti1 <
· · · < tini since the step function Ni(t−) jumps at successive events. However this






























dti1 · · · dtini . (4.7)
The integrand in (4.7) is a product in j, which is invariant to the ordering of
the tij variables. For a point ti = (ti1, . . . , tini)
T ∈ (ai, bi]ni whose elements are not
necessarily in ascending order, let {ti(1), . . . , ti(ni)} be its set of order statistics where
ti(1) < · · · < ti(ni). For any such set of order statistics there are ni! corresponding
points that can be generated via permutation. It follows that (ai, bi]
ni can be par-
titioned into ni! regions, each of which imposes an ordering on the elements of its
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points. The integration region in (4.7) corresponds to one such ordering and the in-
































From the likelihood in (4.4) and density in (4.8), the full conditional likelihood






























In the limit as δ → 0, this PD-SCCS conditional likelihood converges to the SCCS
likelihood in (4.2). Inference for PD-SCCS is based on the conditional likelihood in
(4.9). A key outcome of conditioning on ni is that individuals with no events (ni = 0)
have a likelihood of LcPD,i = 1, and thus make no contribution to the estimation. It
follows that only cases (ni ≥ 1) need to be included in the analysis.
Under the original SCCS model, only exposed cases are needed since unexposed
cases (xi(t) ≡ 0 for all t ∈ (ai, bi]) have no effect on β̂ or parameter inference. We
discussed this feature of the SCCS model in Section 3.2.2. For PD-SCCS, however,
unexposed cases can impact the δˆ estimate, which in turn influences β̂ and parameter
inference. Thus, if unexposed cases are available in the data they should be included
in the PD-SCCS analysis. Nonetheless, there is still a substantial reduction in compu-
tational cost compared to an unconditional analysis since the number of cases is often
much smaller than the total number of individuals. For example, data sources used
for postmarketing surveillance can contain tens of millions of individuals, but for a
particular AE the number of cases is typically on the order of one hundred thousand.
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4.3 Optimization and large sample inference
Let θ = (βT, δ)T denote the full parameter vector for our PD-SCCS model. We use
maximum likelihood based on the expression in (4.9) in order to estimate the com-
ponents of θ. Parameter variances can be estimated from the observed information
matrix I(θ) (the negative of the Hessian matrix) derived from the PD-SCCS condi-
tional log-likelihood. We perform optimization via the Newton-Raphson algorithm,
which relies on the score (gradient) vector U(θ) and observed information matrix
I(θ). Expressions for the components of U(θ) and I(θ) are given in (4.10) and (4.11),
respectively. If θ̂
(0)
is taken to be the initial estimate of the full parameter vector,









k = 0, 1, . . . until suitable convergence criteria are met.





Tβdu}/(1 − exp{−δ ∫ bi
ai
exi(v)
Tβdv}). Then the elements of
the score vector U(θ) = (UTβ (θ),Uδ(θ))



































It follows that the components of the observed PD-SCCS information matrix I(θ)




























































Standard asymptotic theory for maximum likelihood is applicable when θ lies on
the interior of its parameter space (β ∈ <p, δ > 0), in which case the estimate θ̂ can
be treated as if it is distributed as (θ̂ − θ) ∼ N(0, I−1(θ)). We can use I−1(θ̂) to
estimate the covariance matrix of θ̂, where ĉov(β̂) = Iββ(θ̂) and v̂ar(δˆ) = Iδδ(θ̂).
In the PD-SCCS model, the value δ = 0 lies at the boundary of the parame-
ter space. Moran (1971) considers the asymptotic behavior of maximum likelihood
estimates in the boundary case, which results in nonstandard distributions. Under
the conditions given in Moran (1971), the distribution of δˆ converges to an equal
mixture of a positive half-normal distribution and a point mass at zero. When the
true parameter is δ = 0, the observed information Iδδ(θ̂) estimates the variance of
the full-normal distribution, rather than that of the half-normal mixture distribution.
This adjustment needs to be accounted for when hypothesis testing at δ = 0, which
will be discussed in Section 4.4.2.
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4.4 Simulation experiments
In this section we assess the performance of PD-SCCS based on simulation experi-
ments. In our investigation we simulate data from both the PD-SCCS (δ > 0) and
SCCS (δ = 0) models. We examine PD-SCCS estimation results under a variety of
parameter settings, and compare these results to those obtained from fitting SCCS.
Simulations also allow us to evaluate the accuracy of a one-sided Wald test for δ = 0
and of AIC and BIC model selection criteria.
4.4.1 True model is PD-SCCS
Tables 4.1-4.3 show results of simulating from the PD-SCCS model. In every iteration
we created N = 1000 individuals, all with an observation period of τ = 2500 days, and
ran 2000 iterations for each setting of the parameters. We used a single time-varying
covariate that was an indicator of exposure over time. Values of β were varied to
yield relative event rates of eβ = 0.75, 1, and 1.25 for exposure versus baseline. We
assigned a common baseline rate of eφ to all individuals, which we set to 0.00025,
0.0005, and 0.001. These values correspond to expected total numbers of events of
0.625, 1.25, and 2.5, respectively, in an unconditional Poisson model where the event
rate is eφ. For each combination of eφ and eβ, the positive dependence parameter
varied between δ = 0.00025, 0.0005, and 0.001. Exposures for each individual were
generated by splitting the observation period randomly into between 3 and 8 intervals.
Days on which to start and end these intervals were chosen uniformly throughout the
observation period, and exposure status for each interval alternated between exposed
and unexposed.
Table 4.1 shows MSE and MAD for βˆ when the true model is PD-SCCS. The
SCCS and PD-SCCS models yield similar performance in terms of MSE and MAD
when the level of dependence is small (δ = 0.00025), however the level of error for
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SCCS grows with increasing δ. The difference in accuracy between the models is most
pronounced for large values of the relative event rate eβ and baseline rate eφ.
Table 4.2 shows variance estimation and interval coverage results for β when the
true model is PD-SCCS. SM βˆ denotes the square root of the mean of the v̂ar(βˆ)
estimates over all iterations, where v̂ar(βˆ) = Iββ(θ̂). SE βˆ is the empirical standard
error of the βˆ estimates. Close agreement of SM βˆ and SE βˆ suggests that the
estimates v̂ar(βˆ) are performing well. When fitting the PD-SCCS model, SM βˆ and
SE βˆ are close in value and interval coverage levels are near 95%. On the other hand,
fitting SCCS results in less accurate v̂ar(βˆ) estimates and lower confidence interval
coverage. In particular, when the dependence parameter value is high (δ = 0.001)
observed interval coverage levels all lie below 84%.
Table 4.3 shows results for δˆ when PD-SCCS is the true model. The Mean δˆ
column shows the mean of the δ estimates over all iterations. In general the mean
bias is less than 5% of the estimated standard error SM δˆ, except in cases where the
dependence parameter is high (δ = 0.001). In these cases the value of δ tends to be
underestimated. The estimated SM δˆ and empirical SE δˆ standard errors are close
in value in most cases, with a few exceptions. Interval coverage levels are generally
close to 95% and lie above 88% in all cases. In our simulations, there was no observed
difference between AIC and BIC for the proportion of times that the criteria favored
PD-SCCS over SCCS. Observed proportions for AIC and BIC were greater than 0.998
for all parameter settings, which demonstrates that both criteria are able to correctly
select the PD-SCCS model for the given parameter values.
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Table 4.1: Estimation error for βˆ when PD-SCCS is true model
eβ eφ (×10−4) δ (×10−4) MSE βˆ (×10
−3) MAD βˆ (×10−2)
SCCS PD-SCCS SCCS PD-SCCS
0.75
2.5
2.5 3.02 3.00 4.37 4.36
5 2.23 2.03 3.81 3.61
10 2.14 1.04 3.70 2.57
5
2.5 2.33 2.28 3.84 3.80
5 1.91 1.69 3.43 3.25
10 1.81 0.95 3.40 2.30
10
2.5 1.66 1.75 3.24 3.23
5 1.34 1.13 2.91 2.68
10 1.44 0.52 3.06 1.83
1
2.5
2.5 2.62 2.61 4.06 4.04
5 1.94 1.76 3.52 3.35
10 1.64 0.77 3.24 2.22
5
2.5 2.09 2.08 3.65 3.60
5 1.57 1.35 3.13 2.90
10 1.55 0.58 3.15 1.92
10
2.5 1.36 1.34 2.94 2.88
5 1.07 9.46 2.63 2.45
10 1.12 0.36 2.69 1.50
1.25
2.5
2.5 2.49 2.46 4.00 3.97
5 1.90 1.57 3.43 3.15
10 2.28 0.58 3.82 1.93
5
2.5 1.97 1.89 3.54 3.48
5 1.46 1.18 3.06 2.73
10 2.02 0.45 3.64 1.70
10
2.5 1.14 1.18 2.70 2.65
5 0.98 0.71 2.50 2.12
10 1.73 0.28 3.36 1.34
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Table 4.2: Results for βˆ and v̂ar(βˆ) when PD-SCCS is true model
eβ eφ δ SCCS (×10−2) PD-SCCS (×10−2) 95% CI β (%)
(×10−4) (×10−4) SM βˆ SE βˆ SM βˆ SE βˆ SCCS PD-SCCS
0.75
2.5
2.5 5.39 5.49 5.37 5.48 94.30 94.25
5 4.61 4.70 4.57 4.51 94.85 94.80
10 3.28 4.26 3.17 3.23 83.80 94.45
5
2.5 4.79 4.83 4.77 4.77 94.60 95.25
5 4.10 4.35 4.06 4.12 93.15 94.30
10 2.91 3.80 2.81 3.07 81.20 94.45
10
2.5 3.91 4.08 3.90 4.18 94.25 93.85
5 3.35 3.59 3.32 3.35 92.40 94.75
10 2.38 3.25 2.30 2.28 78.50 95.35
1
2.5
2.5 5.14 5.11 5.12 5.11 95.30 95.30
5 4.29 4.40 4.24 4.19 94.50 95.30
10 2.88 4.05 2.76 2.77 82.50 95.05
5
2.5 4.50 4.58 4.49 4.57 94.85 94.90
5 3.76 3.97 3.71 3.68 93.25 94.90
10 2.52 3.94 2.42 2.41 78.95 95.25
10
2.5 3.61 3.69 3.60 3.66 93.85 94.55
5 3.02 3.27 2.98 3.08 93.45 94.95
10 2.02 3.35 1.94 1.90 75.90 95.05
1.25
2.5
2.5 4.97 4.99 4.95 4.96 94.90 94.85
5 4.05 4.31 3.98 3.96 93.20 95.15
10 2.55 4.20 2.43 2.40 70.00 95.75
5
2.5 4.29 4.44 4.28 4.35 94.40 95.05
5 3.50 3.77 3.44 3.43 92.85 95.05
10 2.21 3.88 2.10 2.12 65.00 95.00
10
2.5 3.39 3.37 3.38 3.44 95.20 95.05
5 2.76 3.07 2.72 2.67 91.35 94.90
10 1.74 3.37 1.66 1.65 57.65 94.40
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Table 4.3: Results for δˆ when PD-SCCS is true model (δ > 0)













2.5 2.50 3.87 3.86 95.10 1 1
5 5.01 3.48 3.47 95.50 1 1
10 9.96 2.88 2.82 94.85 1 1
5
2.5 2.51 3.43 3.38 95.55 1 1
5 4.99 3.08 3.02 95.10 1 1
10 9.95 2.55 3.42 94.20 0.9995 0.9995
10
2.5 2.50 2.80 2.82 95.45 0.9995 0.9995
5 5.00 2.52 2.51 94.90 1 1
10 9.94 2.08 2.03 94.65 1 1
1
2.5
2.5 2.50 3.30 3.34 95.20 0.999 0.999
5 5.00 2.98 3.74 94.25 0.998 0.998
10 9.95 2.48 2.41 94.95 1 1
5
2.5 2.51 2.90 2.98 94.65 0.999 0.999
5 5.01 2.61 2.62 95.60 1 1
10 9.94 2.18 2.15 94.15 1 1
10
2.5 2.50 2.32 2.38 94.60 0.9995 0.9995
5 4.99 2.09 2.37 94.60 0.9995 0.9995
10 9.91 1.74 1.74 91.45 1 1
1.25
2.5
2.5 2.50 2.86 2.91 94.85 1 1
5 5.00 2.60 2.54 95.40 1 1
10 9.93 2.17 2.18 93.25 1 1
5
2.5 2.50 2.47 2.43 95.05 1 1
5 5.00 2.24 2.29 94.65 1 1
10 9.91 1.87 1.87 91.85 1 1
10
2.5 2.50 1.95 2.11 94.90 0.999 0.999
5 5.00 1.77 1.79 94.85 1 1
10 9.89 1.48 1.48 88.05 1 1
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4.4.2 SCCS simulations
Tables 4.4-4.6 show results of simulating from the SCCS model. In every iteration we
generated N = 1000 individuals, all of whom had observation period lengths of τ =
2500 days. We created exposures in the same manner as in the PD-SCCS simulations.
Relative risk due to exposure was set to eβ = 0.75, 1, and 1.25, and the initial baseline
rate for all individuals was set to eφ = 0.00025, 0.0005, 0.001, and 0.002.
Table 4.4 shows MSE and MAD for βˆ when the true model is SCCS. PD-SCCS
and SCCS error levels are closer for higher values of eβ. SCCS generally has a lower
level of error than PD-SCCS according to both metrics, which is sensible since SCCS
is the true model in this case.
Table 4.4: Estimation error for βˆ when SCCS is true model
eβ eφ (×10−4) MSE βˆ (×10
−3) MAD βˆ (×10−2)
SCCS PD-SCCS SCCS PD-SCCS
0.75
2.5 3.91 4.35 4.98 5.26
5 3.17 5.38 4.51 5.17
10 2.11 3.78 3.63 4.02
20 1.15 3.01 2.72 3.26
1
2.5 3.53 3.80 4.77 4.95
5 2.77 3.15 4.19 4.45
10 1.74 2.06 3.34 3.52
20 0.99 1.31 2.47 2.88
1.25
2.5 3.70 3.46 4.87 4.66
5 2.68 2.70 4.11 4.19
10 1.64 1.70 3.21 3.23
20 0.93 1.18 2.43 2.66
Table 4.5 shows variance estimation and confidence interval coverage results for
β when SCCS is the true model. SM βˆ and SE βˆ are close in value and observed
interval coverage levels are near 95% for SCCS, which is expected since SCCS is the
true model. PD-SCCS tends to underestimate the variability of βˆ when the relative
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risk is low (eβ = 0.75). This leads to lower interval coverage, however observed levels
all lie above 91% for the given parameter settings.
Table 4.5: Results for βˆ and v̂ar(βˆ) when SCCS is true model
eβ eφ (×10−4) SCCS (×10
−2) PD-SCCS (×10−2) 95% CI β (%)
SM βˆ SE βˆ SM βˆ SE βˆ SCCS PD-SCCS
0.75
2.5 6.21 6.26 6.21 6.58 95.10 93.65
5 5.52 5.63 5.52 7.26 94.75 92.15
10 4.51 4.59 4.51 6.12 94.00 92.55
20 3.37 3.39 3.37 5.47 95.15 92.45
1
2.5 6.06 5.94 6.06 6.09 95.80 95.00
5 5.31 5.26 5.31 5.53 95.05 93.05
10 4.26 4.17 4.26 4.50 95.55 94.75
20 3.13 3.14 3.13 3.63 94.95 91.35
1.25
2.5 5.98 6.08 5.98 5.87 94.80 94.95
5 5.17 5.18 5.17 5.09 95.00 95.95
10 4.08 4.06 4.08 4.13 95.30 95.25
20 2.97 3.05 2.97 3.44 93.95 91.15
Table 4.6 shows simulation results for δ when fitting PD-SCCS to the SCCS model,
where the true PD-SCCS dependence parameter δ is equal to zero. The first column
gives the mean of the δˆ estimates over all iterations, which for δ = 0 is equivalent to
MAD δˆ. We can see that fitting PD-SCCS yields small positive δˆ estimates, and that
the estimates approach the correct value of zero as the event rate increases.
As discussed in Section 4.3, when the true parameter lies at the boundary δ =
0 the distribution of δˆ approaches an equal mixture of a point mass at zero and a
positive half-normal. The variance of a half-normal is σ2(1 − 2/pi), where σ2 is the
variance of the analogous full-normal distribution. This suggests that the estimate
σ̂2 = Iδδ(θ̂) should be scaled by a factor of 1/2× (1− 1/pi)) for accurate comparison
with empirical standard errors. Table 4.6 shows that the adjusted estimates (Adj.
SM δˆ) and empirical standard errors (SE δˆ) are close in value, which indicates that
Iδδ(θ̂) is an accurate estimate for σ2.
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For the boundary parameter mixture distribution, the 1 − α quantile lies at
√
2σ erf−1(1−2α). Thus to test the hypothesis H0 : δ = 0 (SCCS) against H1 : δ > 0





2 erf−1(1− 2α) = Φ−1(1− α),
where Φ(.) is the standard normal CDF. Observed type I errors for this test
procedure (shown in Table 4.6) are close to the desired α = 0.05 level. To select
between the PD-SCCS and SCCS models, one method would be to fit the PD-SCCS
model and test H0 : δ = 0 as above, where failing to reject H0 suggests that positive
dependence is not present and SCCS may be used. Alternatively one could evaluate
the models based on AIC or BIC, with BIC being more conservative in how often it
will favor the PD-SCCS model. The last two columns of Table 4.6 give the observed
proportion of times that AIC and BIC selected PD-SCCS over SCCS. In this case BIC
correctly favors SCCS more often, whereas AIC has higher error than the 0.05-level
Wald test of δ = 0.
Table 4.6: Results for δˆ when SCCS is true model (δ = 0)
















2.5 1.85 2.56 2.65 5.10 8.25 6.00
5 1.57 2.26 2.30 5.20 8.30 5.00
10 1.25 1.85 1.84 5.00 7.75 4.50
20 1.00 1.38 1.42 5.25 8.50 5.00
1
2.5 1.54 2.20 2.21 5.10 8.05 4.50
5 1.34 1.93 1.91 5.20 8.00 2.50
10 1.10 1.55 1.55 5.20 7.90 4.00
20 0.81 1.14 1.14 5.00 8.05 3.50
1.25
2.5 1.39 1.92 2.01 6.15 9.10 4.50
5 1.12 1.67 1.64 4.65 7.80 4.00
10 0.95 1.31 1.34 5.15 8.10 6.00
20 0.71 0.96 0.95 4.60 7.90 2.50
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4.5 Example data analyses
We will consider two example analyses investigating the relationship between time-
varying drug exposures and recurring MI events. For the outcome of MI, it is plausible
that event occurrences exhibit positive dependence in a manner that is compatible
with our PD-SCCS model. Data are composed of de-identified records from a lon-
gitudinal health insurance claims database. This database includes information on
patient-level prescriptions and diagnoses, and covers approximately 36 million indi-
viduals between the years of 2000 and 2007.
4.5.1 Vioxx and myocardial infarction
Vioxx (rofecoxib) is a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID)
manufactured by Merck & Co, Inc. that went on the market in May 1999. Its primary
indication was for the management of osteoarthritis symptoms and acute pain. Merck
withdrew Vioxx worldwide in September 2004 due to evidence of an increased risk
of cardiovascular events, including MI (Bresalier et al., 2005). Our objective is to
estimate the strength of the association between Vioxx and MI while allowing for
positive dependence between MI events.
In our database there were N = 163387 individuals who experienced at least one
MI over the course of their observation, which qualifies them as cases for our analysis.
MI events were required to be separated by a window of at least 60 days in order
to minimize double counting. Under this definition, 137933 (84.42%) individuals had
exactly one MI during their observation period, 18230 (11.16%) had two, 4430 (2.71%)
had three, and 2794 (1.71%) had 4 or more. The median observation period length
was 3.3 years, with a 25th percentile of 1.8 years and a 75th percentile of 5.4 years.
For individuals who were exposed to Vioxx, we assumed that the physical exposure
risk would persist during a window of 30 days following the last known availability
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date of the drug. For our analyses we fit both the standard SCCS model and our
PD-SCCS model with Vioxx exposure as the single time-varying covariate.
Table 4.7: Vioxx and MI Results
Parameter (95% CI) SCCS PD-SCCS
βˆ 0.15 (0.10, 0.20) 0.25 (0.20, 0.30)
eβˆ 1.17 (1.11, 1.22) 1.29 (1.22, 1.35)
δˆ (×10−4) - 2.74 (2.65, 2.83)
AIC 2850144 2846761
BIC 2850154 2846781
From the results in Table 4.7, we can see that SCCS estimates an elevated relative
risk of MI due to Vioxx exposure with a 95% confidence interval of (1.11, 1.22). The
estimated relative risk increases under the PD-SCCS model, with a confidence interval
of (1.22, 1.35). The estimated interval for δ under the PD-SCCS model is (2.65×10−4,
2.83×10−4), and both AIC and BIC favor the PD-SCCS model over SCCS for this
analysis. These results suggest that positive dependence is present between MI events,
which matches the clinical understanding that the occurrence of an MI can increase
an individual’s future risk of MI.
4.5.2 Proton pump inhibitors and myocardial infarction
As a second example, we will compare the SCCS and PD-SCCS models when estimat-
ing the strength of association between proton pump inhibitors (PPIs) and MI. The
main action of PPIs is to reduce gastric acid production, which is helpful for treating
heartburn, inflammation of the esophagus, and ulcers. In 2007 the FDA performed
a safety review of two PPIs, Prilosec (omeprazole) and Nexium (esomeprazole), af-
ter data from two long-term studies raised concerns about an increased risk of heart
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problems associated with this class of drugs. After a full review, the FDA stated
that “long-term use of omeprazole or esomeprazole is not likely to be associated with
an increased risk of heart problems” and recommended that patients continue use of
these drugs as prescribed (FDA, 2007a).
The relevant individuals for our analysis are those who had at least one MI during
their period of observation. This is the same group of individuals we considered in
the previous example with Vioxx and MI.
Table 4.8: PPI and MI Results
Parameter (95% CI) SCCS PD-SCCS
βˆ 0.08 (0.06, 0.10) -0.03 (-0.05, -0.01)
eβˆ 1.08 (1.06, 1.10) 0.97 (0.95, 0.99)
δˆ (×10−4) - 2.76 (2.66, 2.86)
AIC 2850107 2846830
BIC 2850117 2846850
From the results in Table 4.8 we see that the SCCS confidence interval for eβ is
(1.06, 1.10), suggesting a slightly elevated relative risk of MI during periods of PPI
exposure. With the PD-SCCS model, however, the estimated risk is reduced and the
confidence interval (0.95, 0.99) for eβ is close to 1, which is more consistent with the
findings of the FDA’s 2007 review. Results for the PD-SCCS dependence parameter
δ are similar to those in the Vioxx and MI example, and both AIC and BIC favor the
use of PD-SCCS for this analysis.
4.6 PD-SCCS vs. Farrington and Hocine (2010)
Farrington and Hocine (2010) present an approach that extends SCCS to allow for
within-individual event dependence. This method treats the vector of observed event
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times ti = (ti1, . . . , tini)
T for each individual i as a single point in an ni-dimensional
region, where ni denotes the number of events experienced by individual i. This
region is restricted to Qi(ni) = {ti ∈ (ai, bi]ni : ti1 < · · · < tini} since the components
of ti are ordered by time and no event times can occur outside of the observation
window (ai, bi]. The standard SCCS model assumes that events are realizations of a
one-dimensional Poisson process and conditions upon the observed number of events
ni. In Farrington and Hocine (2010), however, the event time vector ti is treated as a
single point arising from an ni-dimensional Poisson process. In this multi-dimensional
framework, conditioning on ni is equivalent to conditioning on the occurrence of a
single point in the region Qi(ni).
We will let xi be shorthand for the full covariate history for person i, i.e. xi =
{xi(t) : t ∈ (ai, bi]}. If λi(t1, . . . , tni | xi) is the intensity of the ni-dimensional Poisson
process onQi(ni), the likelihood of a single multidimensional event ti is (Cressie, 1993)







λi(si1, . . . , sini | xi)dsi1 · · · dsini
}
.
It follows that the conditional likelihood of ti given the occurrence of one such
point in Qi(ni) takes the form of a normalized multidimensional intensity, i.e.
Lci =
p(an event at ti)
p(one event in Qi(ni))
=
λi(ti1, . . . , tini | xi)∫ ·· · ∫
Qi(ni)
λi(ui1, . . . , uini | xi)dui1 · · · duini
, (4.12)
where the exponential term ends up dropping out of the model. Farrington and
Hocine assume that the ni-dimensional Poisson intensity can be written in the form
λi(ti1, . . . , tini | xi) =
ni∏
j=1
λi(tij | xi)×Hni(ti1, . . . , tini), (4.13)
where the product term is made up of independent univariate intensities λi(t |
xi), and the Hni(.) function determines the dependence between events. Under the
intensity in (4.13), the conditional likelihood takes the form
Lci =
∏ni
j=1 λi(tij | xi)×Hni(ti1, . . . , tini)∫ ·· · ∫
Qi(ni)
∏ni
k=1 λi(uik | xi)×Hni(ui1, . . . , uini)dui1 · · · duini
. (4.14)
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From (4.14) we can see that multiplicative terms of λi(t | xi) that are fixed in time
will cancel out of the conditional likelihood, as they do in the original SCCS model.
Similarly, fixed multiplicative terms in Hni(.) will also drop out of the conditional
likelihood. Different possible choices for the dependence function Hni(.) are explored
in Farrington and Hocine (2010). In their extension, the vector of event times ti
is treated as a single realization of an ni-dimensional process, which is analogous
to the perspective we used to evaluate the integral in the denominator of the PD-
SCCS conditional likelihood in (4.7). However, Farrington and Hocine’s method does
not accommodate the type of positive event dependence that is represented in the
PD-SCCS model.
If we approach the PD-SCCS model from an analogous multidimensional perspec-
tive, we can write out the ni-dimensional PD-SCCS intensity for i as
λPD,i(ti1, . . . , tini | xi) =
ni∏
j=1
(eφi + δ(j − 1)) e xi(tij)Tβ. (4.15)
Our event vector ti is also restricted to the region Qi(ni), as it was for Farrington

























dsi1 · · · dsini
.
The portion of the intensity that is fixed in time, i.e.
∏ni
j=1(e
φi + δ(j − 1)) drops
out of the conditional likelihood as we would expect. However, the exponential term
that involves the birth process component remains in the likelihood since it is depen-
dent on the observed event times ti1, . . . , tini . Due to this additional birth process
component, our model cannot be written as a multidimensional Poisson process since
in the Poisson case the exponential term would drop out of the likelihood, as it did
in (4.12). As a consequence, Farrington and Hocine’s method is not able to represent
the positive event dependence in the PD-SCCS model.
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Chapter 5
Discussion
In Chapter 2 we introduced how the simple SCCS model can be used to identify new
drug-AE associations in an active surveillance system based on LODs. We presented
a unique development of the SCCS model from a perspective that differs from Far-
rington’s presentation and connects SCCS with the well-established FEP model in
econometrics literature. This connection opens promising directions for future work;
for example Hausman et al. (1984) discuss a negative binomial version of the model
that can overcome problems of overdispersion in Poisson counts, and Wooldridge
(1997) proposes method of moments estimators that can be applied without impos-
ing a strict exogeneity assumption, i.e. without requiring assumption (ii) in which
future exposure values must be determined independently of the past event process.
The features of SCCS make it an appealing choice for postmarketing surveil-
lance. SCCS automatically controls for fixed multiplicative individual-level baseline
covariates, which is an advantage in the context of surveillance since insurance claims
databases provide a limited amount of baseline information. This also prevents the
need to estimate individual parameters, which in our problem would require high-
dimensional optimization. SCCS depends only on data from exposed cases, which
saves a considerable amount of computation since in LODs there are typically a mod-
CHAPTER 5. DISCUSSION 73
est number of exposed cases compared to the total number of individuals.
We identified five drug-AE pairs for analysis in order to investigate whether ap-
plying the simple SCCS aproach for surveillance in claims data could lead to earlier
detection of suspected associations than the usual DP method based on AERS data.
Results suggest that earlier detection may have been possible in the case of the Vioxx-
MI and estrogen-MI pairs. In addition, the simple SCCS analysis did not pick up
the false negative pair (simvastatin-cataract), which had previously been identified in
AERs data. As further evaluation of the simple SCCS method we looked at results
of the drug-AE pair classification problem, which is based on the HOIs and DOIs
defined by OMOP. We compared simple SCCS to the DP and OS approaches, which
are both currently in use for surveillance. Results showed that simple SCCS had good
performance for our evaluation metrics across the majority of the databases. We are
currently working with OMOP to compare simple SCCS to a broader group of surveil-
lance methods, and results of this evaluation will soon be available (see Ryan et al.
(2011) for preliminary assessments). Our analyses are part of the OMOP project’s
large scale effort to evaluate surveillance methods based on empirical results. System-
atic assessment of methods for postmarketing surveillance is a considerable task that
has not been undertaken before, and results of these evaluations will be important in
informing a future nation-wide active surveillance system.
In Chapter 3 we focused on extensions of the SCCS model in order to adapt it
for the high-dimensional problem of postmarketing surveillance. First, we introduced
the multiple SCCS model in which multiple drug exposures are incorporated as time-
varying covariates. The multiple SCCS framework also allows drug interaction effects
to be included, which is beneficial since patients often take multiple drugs concur-
rently. Second, we proposed taking a Bayesian approach to regularize the regression
model. In our Bayesian multiple SCCS model, regularization restricts the size of
the parameter estimates and prevents the difficulties of overfitting that are encoun-
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tered when using maximum likelihood for high-dimensional regression models. The
Laplacian prior has the added benefit of inducing sparsity in the estimates so that
covariates without an appreciable effect are selected out of the model. Lastly, we
propose using the CCD algorithm for MAP estimation, which is an efficient approach
for large problems and makes optimization tractable in high-dimensional settings.
Our Bayesian multiple SCCS approach has demonstrated good performance for clas-
sifying drug-AE pairs into positive associations and negative controls based on our
analyses of OMOP databases. Bayesian SCCS generally performs better than or as
well as BLR; it is possible that these gains are due to AEs being modeled as recurrent
outcomes or to the self-controlled (within-person comparison) aspects of SCCS. Both
the Bayesian SCCS and BLR approaches tend to do better than methods based on
marginal associations (simple SCCS, DP, and OS), which suggests that adjusting for
potential confounders leads to improved performance. As noted in Section 3.5.2, our
performance evaluation is subject to the limitations of the 53 drug-AE pair classifi-
cation experiment, and further investigations may lead to greater insight regarding
methods assessment.
There are many avenues for extensions and future work, and several approaches to
modeling that can be built into the SCCS analysis in its current form. For instance, if
it is believed that drug exposures may influence patients in different ways according
to sex or age, one could include interaction effects between exposure and sex (or
age) rather than having a common drug exposure parameter across all individuals.
If certain drug effects are thought to accumulate over time, time-varying cumulative
drug exposure covariates (e.g. that count the total number of days an individual
has been exposed to the drug thus far) could also be directly incorporated. We may
also want to adjust for the presence of certain health conditions in the patients in
our analysis. For example, a condition may be indicative of deteriorating health over
time, which would increase the frequency of AEs, drugs may have unusual effects on
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people who have particular conditions, or patients may be more likely to experience
AEs that are related to underlying health conditions, regardless of what drugs they
are exposed to.
Another direction for future work is hierarchical modeling, which provides a way
for us to incorporate knowledge about the relationship structure of both drug expo-
sures and AE outcomes into our model. For example, drugs can be grouped into larger
drug classes based on their chemical compounds. We would expect that drugs within
a drug class would have exposure effects that are similar and that drugs in different
classes would have effects that are unrelated. We can extend our Bayesian multiple
SCCS approach in a natural way to build in hierarchical structure and borrow strength
across drug classes. Common priors can be imposed on classes of drugs, rather than
treating all drugs as a priori independent, which was our perspective in Chapter 3.
Figure 5.1 shows a schematic of a possible hierarchical modeling approach for drug
classes. Letting d = 1, . . . , D index drug classes, one strategy would be to place a
Normal prior over the drug effects within a class such that βj | µ[d] ∼ N(µ[d], σ2[d]) if
drug j is in class d. This shrinks individual βj’s toward a common drug class effect
µ[d]. A Normal hyperprior could then be placed on the drug class effects themselves,
i.e. µ[d] ∼ N(0, σ2µ), in order to shrink these class estimates toward zero.
Figure 5.1: Hierarchical modeling approach with shrinkage of drug exposure effects βj






Following similar reasoning, we could group AE outcomes into larger classes based
on which body systems are affected by the relevant health condition. For hierarchical
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modeling of AE classes, one could put a common prior over exposure estimates for
AE outcomes in a common class. This would tie together drug effect estimates across
different AE outcomes, whereas previously we had focused on the case where there
is a single outcome AE of interest. Figure 5.2 shows a schematic of a hierarchical
modeling strategy based on classes of AEs. If c = 1, . . . , C indexes health conditions
that correspond to AEs, one could place a prior on the jth drug exposure parameter
so that βj | µ(c)j ∼ N(µ(c)j , σ2(c)) for all AEs that fall into condition class c. This
would shrink individual drug j effects toward a common estimate for that drug within
a condition class, and we could then impose a hyperprior µ
(c)
j ∼ N(0, σ2µ) on the
condition class estimates for the jth drug exposure.
Figure 5.2: Hierarchical modeling with shrinkage of drug effect estimates toward a common











































We proposed the Bayesian multiple SCCS approach in Section 3.3 in order to deal
with complications of high-dimensionality. In our approach inference is based on MAP
estimates, but in a fully Bayesian analysis we would ideally obtain an estimate of the
full posterior distribution via MCMC or another sampling procedure. In our high-
dimensional surveillance problem such techniques are computationally prohibitive. In
order to estimate the variability of and find confidence regions for our MAP estimates
we may be able to rely on methods that approximate the posterior. For example, vari-
ational approximations are used for Bayesian analyses (Hinton and van Camp, 1993;
Bishop, 2006) and the integrated nested Laplace approximations (INLA) introduced
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in Rue and Martino (2009) provide another promising alternative. Further investiga-
tion is needed to determine how accurately these approximation-based methods can
estimate posterior variability in our analysis.
We apply our Bayesian multiple SCCS analysis and CCD optimization using an
efficient C++ implementation. To further reduce computation time, we are working
with collaborators on an implementation that makes use of Graphics Processing Units
(GPUs). These processors were originally developed to render high-end 3D graphics,
but can be programmed for parallel processing at a fine scale. Each GPU contains
multiple processor cores, which are used to apply a common operation to multiple
elements of a data array. For procedures that fall into this single instruction, multiple
data (SIMD) paradigm, this method of processing leads to substantial computational
speed-ups (Suchard et al., 2010). CCD is an inherently sequential algorithm that is
dependent on iterative updates. However GPU parallelization happens at the scale
of the matrix operations that occur inside of these sequential iterations. The matrix
operations involved in our algorithm lend themselves to the SIMD framework, and
we have seen promising results with greater than an 80-fold speed-up using a basic
implementation.
In our Bayesian multiple SCCS model, one needs to choose a value for the Normal
σ2β or Laplacian λ hyperparameters. One approach for setting this parameter is
through cross-validation, which involves searching through a range of possible values
and selecting the one that performs the best over disjoint random subsets of hold-out
data. Cross-validation is a computationally costly procedure that would ordinarily be
intractable for our problem. However due to its high speed, our GPU implementation
makes cross-validation tractable even in the large-scale problem of surveillance. We
are currently working on modifying our implementation so that results can be run
on OMOP databases, which would allow us to determine whether selecting cross-
validated hyperparameters improves method performance.
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In Chapter 4 we presented the PD-SCCS model, which allows event risk to increase
additively when an event occurs while maintaining the desirable properties that arise
from conditioning in the SCCS model. This model circumvents assumption (i) for
the SCCS model, which requires conditional independence between event occurrences.
Our example analyses of the association between Vioxx and MI (Section 4.5.1) and
PPIs and MI (Section 4.5.2) demonstrate that accounting for the presence of posi-
tive event dependence by using PD-SCCS rather than SCCS can lead to meaningful
differences between relative risk estimates. It is thus important to consider whether
positive event dependence may be present between event occurrences when choosing
an analysis method. If no event dependence is present, the simulation results in Sec-
tion 4.4.2 show that PD-SCCS will approximate SCCS by estimating δ to be close to
zero. Our simulations in Section 4.4 indicate that one can select between PD-SCCS
and SCCS models by using AIC or BIC, or by using the one-sided Wald test of δ =
0 presented in Section 4.4.2.
In our PD-SCCS model development we assumed a common dependence param-
eter δ for all individuals. This assumption may be too restrictive for certain types of
analyses, in which case δ can instead be permitted to vary with relevant fixed covari-
ates such as sex or baseline health measures. Suppose there are L such covariates,
and for person i the associated covariate vector is denoted by zi = (zi1, . . . , ziL)
T.
The dependence parameter can be written as a function of zi in the form
δ = δ(zi) = e
ψTzi ,
for person i where ψ = (ψ1, . . . , ψL)
T is the vector of effects for zi. Exponentiation
maintains the positivity of δ(zi) and results in zi having a multiplicative effect on
the dependence parameter. In order to make use of this more flexible form, the δ
parameter may be replaced by δ(zi) in the PD-SCCS expressions for person i. If we
use this δ(zi) form for dependence, the expressions that we have presented for the
conditional likelihood in (4.9) and large sample inference presented in Section 4.3
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carry through in a straightforward manner.
Future work extending our PD-SCCS model could investigate whether we can
incorporate other types of event dependence and still maintain the advantages that
arise from conditioning. For instance, there may be situations where the baseline risk
is reduced after an event occurence (a negative event dependence model), the risk is
only altered temporarily, or the effect on the risk decays over time.
The PD-SCCS model that we have presented circumvents conditional indepen-
dence assumption (i) in a particular manner. As discussed in Section 2.2, assumption
(ii) is also likely to be violated in practice. For example, if an individual experiences
an MI or another traumatic health event on a particular day this may effect whether
or not they fill their prescribed medications on subsequent days. Approaches that ad-
dress this restriction within the framework of SCCS include Farrington et al. (2009);
Kuhnert et al. (2010); Roy et al. (2006). Farrington et al. (2009) and Kuhnert et al.
(2010) use methods based on consistent estimating equations. Roy et al. (2006) avoids
the restriction by jointly modeling the distribution of exposures and AE outcomes.
As mentioned previously, in econometrics literature assumption (ii) corresponds to
strict exogeneity. Investigating how this is handled in FEP models may provide some
insight into how we can account for this in our analysis.
The SCCS-based models that we have presented also make the implicit assumption
that, for person i, the length τi of the observation period is determined independently
of the event process. Under this assumption the distribution of observation lengths is
ignorable, i.e. τi is conditionally independent of the event times given the covariate
process, and thus we do not need to explicitly condition on or specify a distribution
for τi in our model. Roy et al. (2006) and more recently Farrington et al. (2011)
present methods for avoiding this assumption in the SCCS model. Non-random drop-
out can occur in the context of surveillance; some AEs may increase the risk of
mortality following event, which would result in dependence between event times and
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Appendix A
Concavity of the SCCS
log-likelihood
The CCD optimization algorithm presented in Section 3.4 depends on the convexity
of the objective function to be minimized. We can show that the multiple SCCS log-
likelihood in (3.2) is concave, and thus the negated log posterior function is convex
for both the Normal and Laplacian priors.
From (3.2), and dropping the *’s for convenience, the log-likelihood for multiple
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In order to verify that the Hessian of the log-likelihood is negative semidefinite,
we need to show that for any (p× 1) vector m = (m1, . . . ,mp)T 6= 0, mTHm ≤ 0.
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2 − (aTi ai)(bTi bi)
]
The Cauchy-Schwarz inequality says that (aTa)(bTb) ≥ (aTb)2 for any vectors a
and b. From this inequality, we know that (aTi bi)
2 − (aTi ai)(bTi bi) ≤ 0 for every i.
We also know that ni/(a
T
i ai)
2 > 0 for every i, so mTHm ≤ 0 and the Hessian H is
negative semidefinite. This shows that the log-likelihood lc is a concave function in
the parameter vector β.
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Appendix B
Equivalence of SCCS and the
conditional within-day logistic
model
We start with the derivation of the within-day logistic (Bernoulli) model. As noted at
the end of Section 2.2, the number of events yid is either 0 or 1 on day (i, d), and the
p drug exposure status indicators are given by xid = (xid1, . . . , xidp)
T. The outcome
yid on day can be modeled as a logistic regression for day (i, d) which is specified as
log
[
p(yid = 1 | xid)
p(yid = 0 | xid)
]
= φi + β
Txid
where φi gives the baseline individual log-odds of an event for person i, and drug ex-
posures xidj act multiplicatively on the odds. It follows that the individual likelihood
contribution for person i under this model is



















d yid. From the factorization theorem we can see that ni is sufficient
for φi, as it was in the Poisson-based SCCS model derivation in Section 2.2. By
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conditioning on ni, we can remove φi from the likelihood expression. This results in
an individual conditional likelihood contribution for person i of the form
p(yi | xi1, . . . ,xiτi , ni) =
p(yi | xi1, . . . ,xiτi)













For the SCCS model, the Poisson likelihood contribution is

















= 1 and this term can
be removed from the likelihood expression. Conditioning on the sufficient statistic ni
yields the conditional likelihood contribution for person i, which takes the form












In this case the SCCS likelihood for person i in (B.2) is the same as the conditional
logistic within-day likelihood for i given in (B.1), so the models are equivalent. In
this setting we are discretizing time into days, where at most one event can occur
per day. This is analogous to letting days be the smallest unit of time in which an
event can occur in the derivation of the non-homogeneous Poisson process that SCCS
is based on (e.g. see Cook and Lawless, 2007). Making this assumption is effectively
equivalent to assuming that the process is Bernoulli within each day.
In our presentation of the SCCS model, the denominator in (B.2) was evaluated in
closed form. To do this we can think of the process occurring in continuous time as in
the derivation of SCCS in Section 4.2.2, and make use of the notation corresponding
to that derivation. There the event rate was modeled as λi(t | Hi(t)) = eφi+xi(t)Tβ,
as given in equation (4.1). Thus the equivalent expression for the denominator term










Tβdti1 · · · dtini .
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Due to the symmetry of the integrand with respect to permutations of the tij’s
(see the PD-SCCS model derivation in Section 4.2.3 for a detailed description), the

















With this closed form expression for the denominator, the conditional likelihood
expression matches the one given in (4.2) for SCCS in continuous time.
